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1. 
TRANSGENIC SOYBEAN PLANTS 
EXPRESSING ASOYBEAN HOMOLOG OF 
GLYCINE-RICH PROTEIN 7 (GRP7) AND 
EXHIBITING IMPROVED INNATE 
IMMUNITY 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit under 35 U.S.C. 119(e) to 
U.S. Application No. 61/532,526 filed Sep. 8, 2011, the 
entirety of which is incorporated by reference herein. 
FEDERALLY SPONSORED RESEARCHOR 
DEVELOPMENT 
The U.S. Government has certain rights in this invention 
pursuant to Grant No. R01 AI069146 awarded by the 
National Institute of Health. 
TECHNICAL FIELD 
This disclosure generally relates to Soybean plants that 
have been genetically-engineered to improve their innate 
immunity. 
BACKGROUND 
The phytopathogenic bacterium, Pseudomonas syringae, 
can Suppress both pathogen-associated molecular pattern 
(PAMP)-triggered immunity (PTI) and effector-triggered 
immunity (ETI) by the injection of type III effector (T3E) 
proteins into host cells. T3Es achieve immune Suppression 
using a variety of strategies including interference with 
immune receptor signaling, blocking RNA pathways and 
vesicle trafficking, and altering organelle function. 
Based, at least in part on the experimental results described 
herein, this disclosure provides compositions and methods 
that can be used to genetically engineer plants (e.g., soybean 
plants) that are able to exploit this interaction, thereby 
increasing the innate immunity of the plants. 
SUMMARY 
In one aspect, a method of increasing the innate immunity 
exhibited by a soybean plant is provided. Such a method 
typically includes introducing a transgene into a plurality of 
Soybean cells to produce transgenic Soybean cells, wherein 
the transgene comprises a nucleic acid sequence having at 
least 95% sequence identity to a sequence selected from the 
group consisting of SEQID NO: 15, 17, 19, 21, 23, 25, 27,29, 
31, 33 and 35, wherein the nucleic acid sequence is operably 
linked to a promoter functional in Soybean cells; regenerating 
transgenic soybean plants from the transgenic Soybean cells; 
and identifying at least one of the transgenic Soybean plants 
expressing the transgene. Generally, the at least one of the 
transgenic soybean plants exhibits increased innate immunity 
in response to at least one biotic stress relative to a control 
plant. 
In one embodiment, the transgene comprises a nucleic acid 
sequence having at least 99% sequence identity to a sequence 
selected from the group consisting of SEQID NO: 15, 17, 19. 
21, 23, 25, 27, 29, 31, 33 and 35. In another embodiment, the 
transgene comprises a nucleic acid sequence having a 
sequence selected from the group consisting of SEQID NO: 
15, 17, 19, 21, 23, 25, 27, 29, 31, 33 and 35. In some embodi 
ments, the at least one biotic stress includes a pathogen Such 
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2 
as, without limitation, bacteria, fungi, protozoa a virus, an 
insect, or a wound Such as, without limitation, physical dam 
age caused by people. In some embodiments, the promoter is 
a constitutive promoter. 
In another aspect, a method of increasing the innate immu 
nity exhibited by a soybean plant is provided. Such a method 
typically includes introducing a transgene into a plurality of 
Soybean cells to produce transgenic Soybean cells, wherein 
the transgene comprises a nucleic acid sequence that encodes 
a polypeptide having an amino acid sequence selected from 
the group consisting of SEQID NO: 16, 18, 20, 22, 24, 26, 28. 
30, 32, 34 and 36, wherein the nucleic acid sequence is 
operably linked to a promoter functional in Soybean cells; 
regenerating transgenic Soybean plants from the transgenic 
Soybean cells; and identifying at least one of the transgenic 
Soybean plants expressing the transgene. Generally, the at 
least one of the transgenic Soybean plants exhibits increased 
innate immunity in response to at least one biotic stress rela 
tive to a control plant. 
In some embodiments, the at least one biotic stress includes 
a pathogen Such as, without limitation, bacteria, fungi, pro 
tozoa a virus, and an insect, or a wound such as, without 
limitation, physical damage caused by people. In some 
embodiments, wherein the promoter is a constitutive pro 
moter 
In still another aspect, a transgenic Soybean plant compris 
ing a transgene is provided. Typically, the transgene com 
prises a nucleic acid sequence having at least 95% sequence 
identity to a sequence selected from the group consisting of 
SEQ ID NO: 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 and 35 
operably linked to a promoter functional in Soybean plants. 
Generally, the transgenic soybean plant exhibits an increase 
in innate immunity. 
In some embodiments, the transgene comprise a nucleic 
acid sequence having at least 99% sequence identity to a 
sequence selected from the group consisting of SEQID NO: 
15, 17, 19, 21, 23, 25, 27, 29, 31, 33 and 35. In some embodi 
ments, the transgene comprises a nucleic acid sequence 
selected from the group consisting of SEQID NO: 15, 17, 19. 
21, 23, 25, 27, 29, 31, 33 and 35. Also provided is seed from 
Such a transgenic plant. 
In yet another aspect, a transgenic soybean plant compris 
ing a transgene is provided. Typically, the transgene com 
prises a nucleic acid sequence that encodes a polypeptide 
having an amino acid sequence selected from the group con 
sisting of SEQID NO: 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 
and 36 operably linked to a promoter functional in soybean 
plants. Generally, the transgenic soybean plant exhibits an 
increase in innate immunity. Also provided is seed from Such 
a transgenic plant. 
In another aspect, an isolated nucleic acid having at least 
95% sequence identity to a sequence selected from the group 
consisting of SEQID NO: 15, 17, 19, 21, 23, 25, 27, 29, 31, 
33 and 35 is provided. In some embodiments, the isolated 
nucleic acid has at least 99% sequence identity to a sequence 
selected from the group consisting of SEQID NO: 15, 17, 19. 
21, 23, 25, 27, 29, 31, 33 and 35. In some embodiments, the 
isolated nucleic acid has a sequence selected from the group 
consisting of SEQID NO: 15, 17, 19, 21, 23, 25, 27, 29, 31, 
33 and 35. Also provided is a vector comprising such an 
isolated nucleic acid. In some embodiments, the isolated 
nucleic acid encodes a polypeptide having an amino acid 
sequence selected from the group consisting of SEQID NO: 
16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, respectively. 
In still another aspect, a purified polypeptide is provided. 
Such a polypeptide typically has at least 95% sequence iden 
tity to a sequence selected from the group consisting of SEQ 
US 9, 169,489 B2 
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ID NO: 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36. In some 
embodiments, the purified polypeptide has at least 99% 
sequence identity to a sequence selected from the group con 
sisting of SEQID NO: 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 
and 36. In some embodiments, the purified polypeptide has a 
sequence selected from the group consisting of SEQID NO: 
16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the methods and 
compositions of matter belong. Although methods and mate 
rials similar or equivalent to those described herein can be 
used in the practice or testing of the methods and composi 
tions of matter, suitable methods and materials are described 
below. In addition, the materials, methods, and examples are 
illustrative only and not intended to be limiting. All publica 
tions, patent applications, patents, and other references men 
tioned herein are incorporated by reference in their entirety. 
DESCRIPTION OF DRAWINGS 
FIG. 1 shows that GRP7 overexpression enhances signifi 
cantly PTI responses and resistance to Pseudomonas infec 
tion. Panel (A) shows the oxidative burst triggered by 1 uM 
flg22, 1 uMelf18, 100 ug/mL chitin or in the absence of 
PAMP treatment in Col-2 and transgenic A. thaliana plants 
overexpressing GRP7 (GRP7ox). ROS production is pre 
sented as total photon count during 25 min of treatment and 
measured in relative light units (RLU). Values are meant-SE 
(n-6). Statistical significance was assessed using the ANOVA 
test (P<0.001). Panel (B) shows callose deposition induced by 
1 uM flg22, 1 uMelf18, 100 ug/mL chitin or in the absence of 
PAMP treatment, directly infiltrated in Col-2 and transgenic 
A. thaliana plants overexpressing GRP7 (GRP7ox). Values 
are meantSE (n=24). Statistical significance was assessed 
using the ANOVA test (P<0.001). ND, non detectable. Panel 
(C) shows the growth of Pseudomonas Syringae pv. tomato 
(Pto) DC3000 on Col-2 and GRP7ox plants as measured by 
colony forming units (cfu). Bacterial growth was measured 
four days after spray-inoculation with the wild-type strain 
(WT) or the hrcC" strain. Values are meaniSE (n=4). dai, 
days after-inoculation. Statistical significance was assessed 
using the ANOVA test (P<0.001). Panel (D) shows the disease 
symptoms on Col-2 and GRP7ox plants, four days after 
spray-infection with Pto DC3000 WT. All results shown are 
representative of at least three independent experiments. 
FIG. 2 shows that GRP7 associates with FLS2 at the 
plasma membrane. Panels (A-C) shows the co-immunopre 
cipitation assay performed after transient co-expression of 
GRP7-eCFP or eGFP with EFR-3xHA(A), FLS2-3xmyc (B) 
or BAK1-HA (C) in N. benthamiana plants. Total proteins 
(input) were subjected to immunoprecipitation with GFP 
Trap beads followed by immunoblot analysis. Panel (D) 
shows the co-immunoprecipitation of GRP7 and FLS2 in A. 
thaliana. Co-immunoprecipitation assay performed on Col-0 
and GRP7-GFP plants untreated (-) or treated (+) with 1 uM 
flg22 for 15 min. Total proteins (input) were subjected to 
immunoprecipitation with GFP Trap beads followed by 
immunoblot analysis. Panel (E) shows the bimolecular fluo 
rescence complementation assays between GRP7 and FLS2. 
YFPn, GRP7-YFPn, YFPc and FLS2-YFPc, as well as the 
reverse combinations YFPc, GRP7-YFPc, YFPn and FLS2 
YFPn, were transiently co-expressed in N. benthamiana 
leaves. Plasmolysis experiment was performed in the pres 
ence of 5% NaCl for 5 min. Arrows indicate Hechtian strands. 
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Scale bar corresponds to 20 um. Photographs were taken 2 
days after infiltration and are representative of the total obser 
vations (n=60). All results shown are representative of three 
independent experiments. 
FIG.3 shows that GRP7 associates with translational com 
ponents in Arabidopsis. Co-immunoprecipitation assay per 
formed on Col-0 and GRP7-GFP plants untreated (-) or 
treated (+) with 1 uM flg22 for 15 min. Total proteins (input) 
were subjected to immunoprecipitation with GFP Trap beads 
followed by immunoblot analysis with anti-GFP antibodies 
to detect GRP7-GFP or specific antibodies recognizing the 
translation initiation factor eIF4E and the ribosomal protein 
S14. Asterisks mark eIF4E slower-migrating bands. The 
results shown are representative of three independent experi 
mentS. 
FIG. 4 shows that HopU1 does not affect the protein 
protein interactions between GRP7, FLS2 and translational 
components. Co-immunoprecipitation assay performed on 
Col-0 and HopU1 Arabidopsis plants expressing or not 
GRP7-GFP. Total proteins (input) were subjected to immu 
noprecipitation with GFP Trap beads followed by immunob 
lot analysis with anti-GFP antibodies to detect GRP7 or spe 
cific antibodies recognizing FLS2, the translation initiation 
factor eIF4E, or the ribosomal protein S14. Asterisks mark 
slower-migrating bands forms. The results shown are repre 
sentative of three independent experiments. 
FIG. 5 shows that GRP7 binds FLS2 transcript. Panel (A) 
shows RNA immunoprecipitation in grp7-1 and grp7-1/ 
GRP7-HAA. thaliana lines treated for 30 min with water or 
1 uM flg22. Total proteins were subjected to immunoprecipi 
tation with anti-HA antibodies followed by quantitative RT 
PCR analysis of FLS2, BAK1, GRP7 and GRP8 transcripts 
with specific primers. Values are meant-SE (n=4). The results 
shown are representative of three independent experiments. 
Panels (B) and (C) show that GRP7 binds the 3'UTR of FLS2 
transcripts in vitro. Electrophoretic shift assays performed on 
the 3'UTR of FLS2 RNAs, in presence of increasing concen 
trations of GRP7-GST (B). Competition assay were per 
formed with increasing quantity of unlabeled FLS2 3'UTR 
transcripts to GRP7-GST and P-labeled FLS2 3'UTR tran 
scripts (C). The results shown are representative of three 
independent experiments. 
FIG. 6 shows that HopU1 disrupts GRP7-FLS2 transcripts 
interactions. Panel (A) shows RNA immunoprecipitation in 
HopU1, GRP7-GFP and GRP7-GFP/HopU1 A. thaliana 
lines. Total proteins were subjected to immunoprecipitation 
with GFP Trap beads followed by quantitative RT-PCR analy 
sis of BAK1, FLS2 and GRP7 transcripts with specific prim 
ers. Values are meant-SE (n=4). Panel (B) shows RNA immu 
noprecipitation in grp7, grp7/GRP7-HA and grp7/GRP7 
(R49K)-HAA. thaliana lines. Total proteins were subjected 
to immunoprecipitation with anti-HA matrix beads followed 
by quantitative RT-PCR analysis of BAK1, FLS2, GRP7 and 
GRP8 transcripts with specific primers. Values are meant-SE 
(n=4). The results shown are representative of three indepen 
dent experiments. 
FIG. 7 shows that HopU1 inhibits FLS2 protein accumu 
lation during infection. Panel (A) shows immunoblots with 
specific antibodies detecting endogenous FLS2 in Col-0 dur 
ing bacterial infection after Syringe-inoculation with Pto 
DC3000 (WT: inoculum: 5x107 cfu/mL), Pto DC3000 
AhopU1 (inoculum: 10 cfu/mL), Pto DC3000 hrcC" (inocu 
lum: 10 cfu/mL). hpi, hours post-infection; CBB, Coomassie 
Brilliant Blue. Values correspond to signal intensity of the 
FLS2-specific band from the immunoblots relative to the Zero 
time-point. Panel (B) shows immunoblots with specific anti 
bodies detecting endogenous FLS2 in Col-0 during bacterial 
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infection after syringe-inoculation with Pto DC3000 (WT: 
inoculum: 5x107 cfu/mL), Pto DC3000 AhopU1 (inoculum: 
10 cfu/mL). Pto DC3000 AhopU1 HopU1 (inoculum: 10 
cfu/mL), Pto DC3000 AhopU1 HopU1DD (inoculum: 10 
cfu/mL). hpi, hours post-infection; CBB, Coomassie Brilliant 
Blue. Values correspond to signal intensity of the FLS2 
specific band from the immunoblots relative to the Zero time 
point. Panel (C) shows the FLS2 transcript level as measured 
by quantitative RT-PCR in Col-O plants during bacterial 
infection after syringe-inoculation with Pto DC3000 (WT: 
inoculum: 5x107 cfu/mL), Pto DC3000 AhopU1 (inoculum: 
10 cfu/mL), Pto DC3000hrcC" (inoculum: 10cfu/mL). hpi, 
hours post-infection. Panel (D) shows bacteria growth mea 
Sured during pseudomonas infection in Col-O plants, after 
syringe- (inoculum: 2x10 cfu/mL) or spray-inoculation (in 
oculum: 2x10 cfu/mL) with Pto DC3000 wild-type (WT) or 
the derivated strains AfliC, AhopU1 and AhopU1 AfliC. 
Growth measured by colony forming units (cfu) two and/or 
four days after inoculation. Values are mean+SE (n=4). Sta 
tistical significance was assessed using the ANOVA test 
(P<0.001). dai, days after-inoculation. The results shown are 
representative of three independent experiments. 
FIG. 8 shows GRP7 over-expression in the GRP7ox line. 
Immunoblots with a specific antibody detecting GRP7 in 
Col-2 and the transgenic Arabidopsis thaliana line overex 
pressing GRP7 (GRP7ox). The blot obtained with the anti 
body anti-LHCP (Light Harvesting Chlorophyll a?b Protein) 
served as a loading control. 
FIG. 9 shows that HopU1 suppresses early and late 
immune responses triggered by flg22 in Arabidopsis. Panel 
(A) shows the oxidative burst triggered by 50 nM flig22 or 50 
nMelf18 in Col-0 and transgenic A. thaliana plants express 
ing HopU1-HA under 35S promoter (HopU1). ROS produc 
tion is presented as total photon count during 40 min of 
treatment and measured in relative light units (RLU). Values 
are meantSE (n=12). Statistical significance was assessed 
using the ANOVA test (P<0.001). Panel (B) shows callose 
deposition induced by 1 uM flg22 infiltrated in Col-0 and 
transgenic A. thaliana plants expressing HopU1-HA under 
35S promoter (HopU1). Values are meantSE (n=10). Statis 
tical significance was assessed using the ANOVA test 
(P<0.001). Panel (C) shows the oxidative burst triggered by 
50 nM flg22 in Col-0 and transgenic A. thaliana plants 
expressing HopU1-HA under the control of an estradiol 
inducible promoter (ind HopU1), with or without a 15 uM 
B-estradiol pre-treatment. ROS production is presented as 
total photon count during 40 min of treatment and measured 
in relative light units (RLU). Values are meantSE (n=12). 
Statistical significance was assessed using the ANOVA test 
(P<0.001). Panel (D) shows callose deposition induced by 1 
uM flig22 infiltrated in Col-0 and transgenic A. thaliana plants 
expressing HopU1-HA under the control of an estradiol 
inducible promoter (ind HopU1), with or without a 15 uM 
B-estradiol pre-treatment. Values are meant-SE (n=10). Sta 
tistical significance was assessed using the ANOVA test 
(P<0.001). Panel (E) shows the growth of Pseudomonas 
syringae pv. tomato (Pto) DC3000 on Col-0, HopU1 (35S: 
HopU1-HA) and fls2 plants as measured by colony forming 
units (cfu). Bacterial growth was measured three days after 
spray-inoculation with wild-type Pto DC3000 (WT: inocu 
lum: 10 cfu/mL), Pto DC3000 AhopU1 (inoculum: 10cfu/ 
mL) and Pto DC3000 hrcC" (inoculum: 10 cfu/mL). Values 
are meantSE (n=4). Statistical significance was assessed 
using the ANOVA test (P<0.05). All results shown are repre 
sentative of at least three independent experiments. 
FIG.10 shows that GRP7 interacts with EFR at the plasma 
membrane. Panel (A) shows that EFR and GRP7 interact in 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
6 
yeast two-hybrid assays. The cytoplasmic part of EFR (EFR 
cyt) has been found to interact with GRP7 during a yeast 
two-hybrid Screen and confirmed upon expression of plex A 
EFRcyt and pP42AD-GRP7. Interaction assays were per 
formed in presence or absence of the auxotrophic amino acid 
leucine (Leu). Panel (B) shows the bimolecular fluorescence 
complementation assays between GRP7 and EFR. YFPn, 
GRP7-YFPn, YFPc and EFR-YFPc, as well as the reverse 
combinations YFPc, GRP7-YFPc, YFPn and EFR-YFPn, 
were transiently co-expressed in N. benthamiana leaves. 
Scale bar corresponds to 20 um. Photographs were taken 2 
days after infiltration and are representative of the total obser 
vations (n=60). All results shown are representative of three 
independent experiments. 
FIG. 11 shows GRP7 sub-cellular localization. Panel (A) 
shows GRP7 sub-cellular localisation in the stable transgenic 
on A. thaliana plants 35S::GRP7-GFP line as observed by 
confocal microscopy. Panel (B) shows the localization of 
GRP7-egFP transiently expressed in N. benthamiana and N. 
tabacum as observed by confocal microscopy. 
FIG. 12 shows that HopU1 does not interact with, nor 
ADP-ribosylates, FLS2 protein. Panel (A) shows the co-im 
munoprecipitation assay performed after transient co-expres 
sion of HopU1-HA and FLS2-GFP-His on N. benthamiana 
plants, with (+) or without (-) treatment of the samples with 
1 uM flig22 for 15 min. Total proteins (input) were subjected 
to immunoprecipitation with anti-HA beads followed by 
immunoblot analysis. Panel (B) shows the bimolecular fluo 
rescence complementation assays between HopU1 and 
FLS2. HopU1-YFPnand FLS2-YFPc, as well as the opposite 
combination HopU1-YFPc and FLS2-YFPn, were tran 
siently co-expressed N. benthamiana leaves. Scale bar corre 
sponds to 20 Jum. Photographs were taken 2 days after infil 
tration and are representative of the total observations (n=60). 
Panel (C) shows the in vitro ADP-ribosylation assay per 
formed with recombinant FLS2-GST and HopU1-His on 
Supernatant (sup) and pellet (pell) fractions. The reaction 
between GRP7-GST and HopU1-His has been included as a 
positive control. All results shown are representative of three 
independent experiments. 
FIG. 13 shows that GRP7 interacts with HopU1 in the 
cytoplasm and in the nucleus. Panel (A) shows the co-immu 
noprecipitation of GRP7 and HopU1. GRP7-eCFP and 
HopU1-HA were transiently co-expressed in N. benthamiana 
leaves. Total proteins (input) were subjected to immunopre 
cipitation with anti-HA beads followed by immunoblot 
analysis with anti-GFP antibodies to detect GRP7-eCFP. 
Panel (B) shows the bimolecular fluorescence complementa 
tion assays between GRP7 and HopU1. GRP7-YFPn/c and 
HopU1-YFPc/n were transiently co-expressed in N. 
benthamiana leaves. Scale bar corresponds to 20 Lum. Photo 
graphs were taken 2 days after infiltration and are represen 
tative of the total observations (n=60). All results shown are 
representative of three independent experiments. 
FIG. 14 shows that HopU1 disrupts GRP7-EFR transcript 
interactions. Panel (A) shows RNA immunoprecipitation in 
HopU1-HA, GRP7-GFP and GRP7-GFP/HopU1-HA A. 
thaliana lines. Total proteins were subjected to immunopre 
cipitation with GFP Trap beads followed by quantitative RT 
PCR analysis of BAK1, EFR, and GRP7 transcripts with 
specific primers. Values are meaniSE (n=4). Panel (B) shows 
RNA immunoprecipitation in grp7, grp7/GRP7-HA and 
grp7/GRP7(R49K)-HAA. thaliana lines. Total proteins were 
Subjected to immunoprecipitation with anti-HA matrix beads 
followed by quantitative RT-PCR analysis of BAK1, EFR, 
GRP7 and GRP8 transcripts with specific primers. Values are 
meantSE (n=4). 
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FIG. 15 shows that GRP8 binds FLS2 and EFR transcripts. 
RNA immunoprecipitation in Col-0 and GRP8-HA A. 
thaliana lines. Total proteins were subjected to immunopre 
cipitation with anti-HA beads followed by quantitative RT 
PCR analysis of BAK1, EFR, FLS2, GRP7 and GRP8 tran 
scripts with specific primers. Values are meantSE (n=4). 
FIG.16 shows the nucleic acid and amino acid sequences 
of the soybean genes described herein. The A. thaliana GRP7 
sequences also are shown. 
DETAILED DESCRIPTION 
HopU1, a mono-ADP-ribosyltransferase (ADP-RT) from 
the pathogen, P. syringae, modifies GRP7, an RNA-binding 
protein in the plant. Native GRP7 binds to FLS2 and EFR 
RNA, but this binding is reduced when GRP7 is ribosylated at 
Arg 49 (R49). In addition, plants lacking GRP7 indicate that 
GRP7 plays a role in innate immunity. See, for example, Fu et 
al., 2007, Nature, 447:284-8; and Jeong et al., 2011, J. Biol. 
Chem., 286:43272-81. 
In order to increase the innate immunity of an agricultural 
crop, soybean sequences were identified that have a signifi 
cant amount of homology to GRP7. These sequences were 
cloned and introduced into Soybean plants, and their effect on 
innate immunity was evaluated. Innate immunity also is 
known as non-specific immunity and recognize and respond 
to pathogens immediately but does not confer long-lasting 
immunity to the host. Representative examples of biotic 
stresses include, without limitation, pathogens (e.g., bacteria, 
fungi, protozoa viruses, insects) or a physical lesion or 
wound. 
Nucleic Acids and Polypeptides 
The sequences identified in Soybean have the nucleic acid 
sequences shown in SEQID NOs: 15, 17, 19, 21, 23, 25, 27, 
29, 31, 33 and 35. The term “nucleic acid' refers to a deox 
yribonucleic acid or a ribonucleic acid in single- or double 
Stranded form, sense or anti-sense, and, unless otherwise 
indicated, encompasses known analogues of natural nucle 
otides that hybridize to nucleic acids in a manner similar to 
naturally occurring nucleotides. Unless otherwise indicated, 
a particular nucleic acid sequence includes the complemen 
tary sequence thereof. The term “operably linked’ refers to 
functional linkage between a nucleic acid expression control 
sequence (such as a promoter, signal sequence, or transcrip 
tion factor binding sites) and a coding nucleic acid sequence, 
wherein the expression control sequence affects transcription 
and/or translation of the coding nucleic acid sequence. 
Alignment of two or more sequences may be conducted, 
for example, using any number of methods (e.g., the local 
homology algorithm of Smith and Waterman (1981, Adv. 
Appl. Math. 2:482), the homology alignment algorithm of 
Needleman and Wunsch (1970, J. Mol. Biol. 48:443), the 
search for similarity method of Pearson and Lipman (1988, 
PNAS USA, 85:2444), computerized implementations of 
these algorithms (GAP BESTFIT. FASTA, and TFASTA, as 
provided by, for example, the Wisconsin Genetics Software 
Package, Genetics Computer Group, Madison, Wis.) or 
inspection). The preferred method of alignment uses the 
Basic Local Alignment Search Tool (BLAST) (Altschulet al., 
1990, J. Mol. Biol., 215:403-10) available from ncbi.nlm.ni 
h.gov on the World WideWeb. 
The term "percent sequence identity” as applied to an 
amino acid sequence refers to a polypeptide that has at least 
70% sequence identity (e.g., at least 80%, 90%, 95%, 99% or 
100% sequence identity) compared to another amino acid 
sequence (e.g., SEQID NO: 16, 18, 20, 22, 24, 26, 28, 30,32. 
34 or 36). The term "percent sequence identity” as applied to 
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nucleic acid sequences refers to a nucleic acid sequence that 
has at least 50% sequence identity (e.g., at least 60%. 65%, 
70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence 
identity) relative to another nucleic acid sequence (e.g., SEQ 
ID NOs: 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35). 
Another indication that nucleic acids possess sequence 
identity is if the two nucleic acid molecules hybridize to each 
other under Stringent conditions. Stringent conditions are 
sequence-dependent and will be different in different circum 
stances. Generally, stringent conditions are selected to be 
about 5° C. to about 20° C. (e.g., about 10° C. to about 15° C.) 
lower than the thermal melting point (Tm) for the specific 
sequence (i.e., at a defined ionic strength and pH). The Tm is 
the temperature (i.e., under defined ionic strength and pH) at 
which 50% of a first nucleic acid sequence hybridizes to a 
second nucleic acid sequence. Typically, Stringent conditions 
are those in which the salt concentration is about 0.02 Mat pH 
7 and the temperature is at least about 60° C. For example, 
stringent hybridization conditions can include an initial wash 
in 6xSSC at 42° C. followed by one or more additional 
washes in 0.2xSSC at a temperature of at least about 55° C. 
(e.g., about 60° C. or 65° C.). 
A “purified polypeptide' refers to a polypeptide that has 
been separated from most components which naturally 
accompany it. Typically, a polypeptide is purified when it is at 
least 60%, by weight, free from the proteins and naturally 
occurring organic molecules with which it is naturally asso 
ciated (e.g., at least 75%, 80%, 85%, 90%, 95%, or 99%, by 
weight). Polypeptides may be obtained and purified using, for 
example, extraction from a natural source (for example, a 
plant cell); expression of a recombinant nucleic acid encod 
ing the polypeptide; or chemically synthesizing the protein. 
Purity can be measured by any appropriate method, for 
example, column chromatography, polyacrylamide gel elec 
trophoresis, or by HPLC analysis. Similarly, an "isolated 
nucleic acid refers to a nucleic acid sequence free from the 
nucleic acid sequences that naturally flank it. Nucleic acids 
can be isolated using, for example, conventional molecular 
biology techniques including recombinant technologies. 
Transgenic Soybean Plants and Methods of Making 
Plant expression vectors typically include at least a cloned 
gene operably linked to regulatory sequences and a selectable 
marker. Regulatory sequences can include, without limita 
tion, a promoter (for example, one conferring inducible or 
constitutive, pathogen- or wound-induced, environmentally 
or developmentally-regulated, or cell- or tissue-specific 
expression), a transcription initiation start site, a ribosome 
binding site, an RNA processing signal, a transcription ter 
mination site, and/or a polyadenylation signal. 
Representative promoters include a cauliflower mosaic 
virus (CaMV) promoter and a cassava vein mosaic virus 
(CsVMV) promoter. These promoters confer high levels of 
expression in most plant tissues, and the activity of these 
promoters is not dependent on virally encoded proteins. 
CaMV is a source for both the 35S and 19S promoters. In 
most tissues of transgenic plants, the CaMV 35S promoter is 
a strong promoter. Other useful plant promoters include, 
without limitation, the nopaline synthase (NOS) promoter, 
the octopine synthase promoter, figwort mosaic virus (FMV) 
promoter, the rice actin promoter, and the ubiquitin promoter 
system. 
A selectable marker is used to identify those cells or plants 
that contain and express the plant transformation vector. 
Selectable markers suitable for transgenic plants include the 
aminoglycoside phosphotransferase gene of transposon Tn5 
(Aph II) and genes imparting antibiotic resistance (e.g., those 
encoding resistance to hygromycin, kanamycin, bleomycin, 
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neomycin, G418, Streptomycin, or spectinomycin). Select 
able markers also include genes encoding herbicide resis 
tance (e.g., the bar gene encoding phosphinothricin acetyl 
transferase, which confers resistance to the broad-spectrum 
herbicide, Basta) and other genes that impart herbicide resis 
tance such as glyphosate. 
Upon construction of the plant expression vector, several 
standard methods are available for introduction of the vector 
into a plant host, thereby generating a transgenic plant. These 
methods include 
Agrobacterium-mediated transformation (A. tumefaciens 
or A. rhizogenes) (see, for example, Lichtenstein and 
Fuller, In: Genetic Engineering, Vol 6, Rigby, ed., Aca 
demic Press, London, 1987; and Lichtenstein and 
Draper. In: DNA Cloning, Vol II, Glover, ed., IRI Press, 
Oxford, 1985; U.S. Pat. Nos. 4,693,976, 4,762,785, 
4,940,838, 5,004,863, 5,104,310, 5,149,645, 5,159,135, 
5,177,010, 5,231,019, 5,463,174, 5,469,976, and 5,464, 
763); 
the particle delivery system (see, for example, U.S. Pat. 
Nos. 4,945,050 and 5,141,131); 
microinjection protocols; 
polyethylene glycol (PEG) procedures: 
liposome-mediated DNA uptake; 
electroporation protocols (see, for example, WO 87/06614 
and U.S. Pat. Nos. 5,384,253, 5,472,869, 5,641,664, 
5,679,558, 5,712,135, 6,002,070, and 6,074,877); 
the Vortexing method; or 
the “whiskers' methodology (see, for example, U.S. Pat. 
Nos. 5,302,523 and 5,464,765). 
Plant cells (e.g., protoplasts), plant tissue (e.g., embryonic 
tissue, callus tissue type I and II, hypocotyls, meristem, and 
the like) or seeds can be transformed with a plant expression 
vector as described herein. 
Once introduced into the plant cells, expression (e.g., of the 
selectable marker or of the gene to be expressed) may be 
assayed by any means known to the art, and expression may 
be measured as mRNA transcribed or protein synthesized. 
For example, expression of a nucleic acid sequence can be 
evaluated using Northern blot analysis (Ausubel et al., 2001, 
Current Protocols in Molecular Biology, John Wiley & Sons, 
NY. and Sambrook et al., 1998, Molecular Cloning: A Labo 
ratory Manual, Cold Spring Harbor Laboratory, NY), reverse 
transcription PCR (rtPCR) including quantitative rtf(cR (see, 
e.g., Kawasaki et al., in PCR Technology: Principles and 
Applications of DNA Amplification, Erlich, Ed., Stockton 
Press, 1989; Wang et al., in PCR Protocols: A Guide to Meth 
ods and Applications, Innis et al., Eds. Academic Press, 
1990; and Freeman et al., 1999, Biotechniques 26:112-122 
and 124-125). Additional well-known techniques for deter 
mining expression of a gene include in situ hybridization, and 
fluorescent in situ hybridization (see, e.g., Ausubel et al., 
Current Protocols in Molecular Biology, John Wiley & Sons, 
NY. 2001). Similarly, expression of a nucleic acid sequence 
can be measured at the level of protein production using 
standard protein analysis techniques including Bradford 
assays, spectrophotometric assays, and immunological 
detection techniques, such as Western blotting or immuno 
precipitation with an antibody specific for the desirable 
polypeptide (Ausubel et al., Current Protocols in Molecular 
Biology, John Wiley & Sons, NY, 2001, and Sambrook et al., 
Molecular Cloning: A Laboratory Manual, Cold Spring Har 
bor Laboratory, NY, 1989). 
Once plant cells expressing the desired level of a desirable 
gene product are obtained, plant tissues and whole plants can 
be regenerated therefrom using methods and techniques well 
known in the art. The regenerated plants are then reproduced 
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by conventional means and the introduced genes can be trans 
ferred to other strains and cultivars by conventional plant 
breeding techniques. For example, a transgenic Soybean plant 
as described herein (i.e., expressing or over-expressing one or 
more of the Soybean sequences described herein) can be 
crossed with a second soybean plant and progeny of the cross 
can be selected that express or over-express one or more of the 
Soybean sequences described herein. In some embodiments, 
the progeny (i.e., the F population) can be crossed and an F2 
population produced, or the F progeny can be backcrossed 
with one of the parent lines to produce a BC population. It 
would be understood that any number of plant crosses can be 
performed to produce populations including, without limita 
tion, F. BCF, and BCF populations. 
In accordance with the present invention, there may be 
employed conventional molecular biology, microbiology, 
biochemical, and recombinant DNA techniques within the 
skill of the art. Such techniques are explained fully in the 
literature. The invention will be further described in the fol 
lowing examples, which do not limit the scope of the methods 
and compositions of matter described in the claims. 
EXAMPLES 
Part A 
Overexpression in Arabidopsis 
Example 1 
Plant Material 
Arabidopsis thaliana, Nicotiana benthamiana and Nicoti 
ana tabacum were grown at 20-21°C. with a 10 h-photope 
riod in environmentally controlled chambers. Arabidopsis 
seedlings were grown on plates containing Murashige and 
Skoog (MS) medium (Duchefa) and 1% sucrose at 22°C. 
with a 16 h-photoperiod. 
All experiments were performed in Col-0 background, 
except if indicated otherwise. The fls2 mutant used in this 
study is SALK 093905. The GRP7ox (Col-2/35S:GRP7), 
HopU1 (Col-0135S:HopU1-HA), GRP7-GFP (Col-0/355: 
GRP7-GFP), GRP7-HA (grp7-1/GRP7p:GRP7-HA), GRP7 
(R49K)-HAgrp7-1/GRP7p::GRP7(R49K)-HA) were previ 
ously published (see, for example, Fu et al., 2007, Nature, 
447:284-288; Jeong et al., 2011, J Biol Chem, 286:43272 
43281; Streitner et al., 2008, Plant J., 56:239-50; and Kim et 
al., 2008, Plant J., 55:455-466). The GRP7-GFP/HopU1 line 
was obtained by crossing the GRP7-GFP and HopU1 lines. 
The estradiol-inducible HopU1 line (ind HopU1) was 
obtained by transforming Col-0 with the vector plN604 (de 
rived from pBR8; see, for example Zuo et al., 2000, Plant J., 
24:265-273) carrying HopU1-HA. The expression of HopU1 
was induced by spraying 15uM B-estradiol for 16-20 hours. 
The GRP8-HA (Col-0/35S::GRP8-HA) line was obtained by 
transforming Col-0 with the binary vector pPZP212 carrying 
GRP8-HA. Homozygous lines with a single transgene inser 
tion were used for the experiments. 
Example 2 
PTI Assays 
PAMP treatments (flg22 and elf18 peptides synthetized by 
Peptron, South Korea; shrimp chitin from SIGMA) were 
performed by syringe infiltration of plant leaves or by addi 
tion of the elicitor into the liquid media. Oxidative burst 
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assays were performed on leaf disks incubated in a solution 
containing luminol and peroxidase as previously described 
(see, for example, Zipfel et al., 2004, Nature, 428:764-767). 
Callose deposition was observed after infiltration with a solu 
tion of 1 uMPAMP for 16 hours as previously described (see, 5 
for example, Hannet al., 2007, Plant J., 49:607-618). Callose 
deposits were quantified using PDQuestTM software (Bio 
Rad). 
Example 3 10 
Pseudomonas Infection 
Bacterial strains used in this study were Pseudomonas 15 
syringae pv. tomato (Pto) DC3000 wild-type (WT), Pto 
DC3000 AhopU1 and Pto DC3000 hrcC". For bacterial enu 
meration assays, plants were sprayed with the strains WT 
(inoculum: 10 cfu/mL), AhopU1 (inoculum: 10 cfu/mL) 
and hrcC" (inoculum: 10 cfu/mL), in presence of 0.001% 
(v/v) Silwet L-77. Sprayed plants were then covered with a 
transparent plastic lid for the remaining of the experiment. 
For the other assays, bacteria were infiltrated into Arabidop 
sis leaves with the strains WT (inoculum: 5x10" cfu/mL). 
AhopU1 (inoculum: 10 cfu/mL) and hrcC" (inoculum: 10 25 
cfu/mL). 
Example 4 
Yeast Two-Hybrid 30 
The coding region corresponding to the cytoplasmic part of 
EFR (EFRcyt) was cloned in the plex A vector (Clontech). 
The recombinant pI exA-EFRcyt was used to screen a cDNA 
library prepared from infected Arabidopsis plants (van der 35 
Biezenet al., 2000, PNAS USA,97:3747-52) according to the 
indications of the manufacturer. The coding region of GRP7 
from nucleotide 67 to 528 (corresponding to the region of the 
GRP7 clone identified during the initial screen) was re-cloned 
in the pl342AD vector to re-test the interaction. 40 
Example 5 
Agrobacterium-Mediated Transient Expression for 
Co-Immunoprecipitation, Sub-Cellular Localization 45 
and Bimolecular Fluorescence Complementation 
Experiments 
For the co-immunoprecipitation and Sub-cellular localiza 
tion experiments, the following previously described con- 50 
structs were used: 35S::GRP7-eCFP (Fu et al., 2007, Nature, 
447:284-288), 35S:EFR-3XHA (Schwessinger et al., 2011, 
PLoS Genet., 7:e 1002046), 35S::FLS2-3xmyc (Chinchilla et 
al., 2006, Plant Cell, 18:465-76), 35S:BAK1-HA 
(Schwessinger et al., 2011, PLoS Genet. 7:e 1002046), 35S: 55 
FLS2-GFP-His (Schwessinger et al., 2011, PLoS Genet. 
7:e 1002046) and 35S::HopU1-HA (Fu et al., 2007, Nature, 
447:284-288). The Agrobacterium strains GV3101 carrying 
the indicated constructs were Syringe-infiltrated in Nicotiana 
benthamiana or Nicotiana tabacum leaves at ODoo-0.4–0.6 60 
and samples were collected 2 days post-infiltration. 
For the bimolecular fluorescence complementation assays, 
the coding regions of FLS2, EFR, GRP7 and HopU1 was 
cloned into the BiFC binary vectors, p.AM-PAT-355, as pre 
viously described (Lefebvre et al., 2010, Proc Natl AcadSci 65 
USA, 107:2343-2348). The Agrobacterium strain, GV3101, 
expressing the silencing Suppressor P19 and carrying the 
12 
indicated constructs were syringe-infiltrated in Nicotiana 
benthamiana leaves at ODoo-0.4-0.6. 
Confocal analyses for the sub-cellular localization and 
bimolecular fluorescence complementation experiments 
were performed 2 days post-infiltration using a Leica SP5 
confocal microscope. 
Example 6 
Protein Extraction, Co-Immunoprecipitation and 
Immunoblotting 
Total proteins were extracted in a buffer including 100 mM 
Tris-HCl pH 7.5, 150 mM. NaCl, 5 mM EDTA, 5% glycerol, 
10 mM DTT, 0.5% Triton X-100, 1% gepal and protease 
inhibitors (Sigma). For co-immunoprecipitation, anti-HA 
beads (Roche) or anti-GFP-TRAP-A beads (Chromotek) 
were incubated with total proteins and then washed with the 
extraction buffer. Proteins were fractioned on SDS-PAGE, 
transferred onto PVDF membranes (Bio-Rad) and then 
detected using specific antibodies. FLS2 was detected using 
specific polyclonal antibodies raised in rabbit as primary 
antisera. The anti-S14-1 antibodies were obtained from a 
commercial Supplier (Agrisera, Sweden). The rabbit anti 
eIF4E antibody was a kind gift from Prof. A. Maule (John 
Innes Centre, Norwich, UK). Epitope-tagged proteins were 
detected with a peroxidase-conjugated anti-HA-HRP (Santa 
Cruz); mouse monoclonal anti-GFP antibodies (AMS); or 
anti-HRPantibodies (Santa Cruz). The secondary anti-rabbit 
HRPantibodies (Sigma) were used when appropriate. Immu 
nodetection was performed with ECL chemiluminescence 
reagent (GE). Tandem mass spectrometry experiments were 
performed as previously described (Fu et al., 2007, Nature, 
447:284-288). 
Example 7 
In Vitro ADP-Ribosylation Assay 
HopU1-His, GRP7-GST and FLS2-GST were affinity-pu 
rified from Escherichia coli BL21 and the purity of the pro 
teins was examined by SDS-PAGE. The ADP-ribosylation 
assay was performed as previously described (Fu et al., 2007, 
Nature, 447:284-288). 
Example 8 
RNA-Immunoprecipitation Assay 
After UV-crosslinking treatments (120 MJ, 3 times using 
UV StratalinkerTM 2400, Stratagene), total proteins were 
extracted in extraction buffer including 50 mM Tris-HCl pH8. 
150 mMNaCl, 2.5 mM EDTA, 10% glycerol, 10 mM PMSF, 
10 units/mL RNaseCUTTM (Invitrogen) and protease inhibi 
tors (Sigma). After centrifugation, the Supernatant was incu 
bated with anti-HA affinity matrix (Roche) or anti-GFP 
TRAP-A beads (Chromotek). After this incubation, the beads 
were washed and the RNA-GRP7 complexes were eluted by 
incubating at 60° C. for 15 min in the elution buffer (1% SDS, 
0.1 M NaHCO). A proteinase K treatment for 1 hour at 60° 
C. was then followed by RNA extraction and quantitative 
RT-PCR. 
In each experiment, transcript levels from the input were 
normalized in comparison to the control samples (grp7/ 
GRP7-HA in FIGS. 1A, 6B and 14B; HopU1 in FIGS.6A and 
14A; and Col-0 in FIG. 15). The normalization of the tran 
script levels after RNA-IP was performed in comparison to 
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the GRP7 transcript level in grp7/GRP7-HA or GRP7-GFP 
samples (FIGS. 5A, 6A-B, 14A-B) or the GRP8 transcript 
level (FIG. 15). 
Example 9 
Quantitative RT-PCR 
After RNA extraction (Tri Reagent, Sigma-Aldrich), first 
strand cDNA was synthesized using the SuperScript II 
Reverse Transcriptase (Invitrogen). Quantitative PCRs were 
performed from 1.5uL of cDNA with SYBR(R) Green Jump 
StartTM Taq ReadyMixTM (Sigma-Aldrich) on a PTC-200 
Peltier Thermal Cycler (MJ Research, Waltham, Mass.). 
Primers used have the following sequence: 
Ubox (At5g154OO) : 
(SEQ ID NOS : 1 & 
s' - TGCGCTGCCAGATAATACACTATT-3' 
and 
s' - TGCTGCCCAACATCAGGTT-3' 
FLS2 (At 5g46330) : 
(SEQ ID NOS : 3 & 
5 - ACTCTCCTCCAGGGGCTAAGGAT-3' 
and 
5'-AGCTAACAGCTCTCCAGGGATGG-3 
EFR (At 5g2O480) : 
(SEQ ID NOS : 5 & 
5 - CGGATGAAGCAGTACGAGAA-3' 
and 
5 - CCATTCCTGAGGAGAACTTTG-3 
BAK1 (At 4.g3343O) : 
(SEQ ID NOS : 7 & 
5'-ACCGCCTCCTATCTCTCCTACACC-3' 
and 
s' - CTGGGTCCTCTTCAGCTGGTACA-3' 
GRP7 (At2g2166O) : 
(SEQ ID NOs: 9 & 10) 
5'-TGATGACAGAGCTCTTGAGACTGCC-3 
and 
5'-TCCTCCTCCACCCTCGCGTCTACCGCCGCCA-3' 
GRP8 (At 4.g3926O) : 
(SEQ ID NOS : 11 & 12) 
5 - CAATGATGAAGATCTTCAAAGGACG-3 
and 
s' - CTCGTAACCACCACCGCCTCCTCCTGAGTATCC-3' 
Example 10 
Electrophoretic Mobility Shift Assay 
The 3'UTR sequence of FLS2 was amplified with the 
upstream primer GATGGTACCGAAGTTTAGCAG 
CAAAGC (SEQ ID NO:13) and the downstream primer 
GAGCTCGAGGTTCATCAAAACCAAATTTC (SEQ ID 
NO:14). The amplified fragment was subcloned into the plas 
mid p3SK(-) (Stratagene) and transcribed with T7 poly 
merase (Promega) in the presence of 10 uCi 'PCTP. The 
FLS2 3'UTR binding affinity was analyzed with purified 
GRP7-GST in 20 mM HEPES, pH7.5, 100 mM NaCl, 1 mM 
MgCl2, 0.01% NP-40, 10 U SUPERase-InTM (Ambion), and 
50 ng of 'P-labeled FLS2 3'UTR. For competition assays, 
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unlabelled FLS2 3'UTR transcripts were added into the mix 
ture of 2 mM GRP7-GST and 50 ng of P-labelled FLS2 
3-UTR transcripts. The bound and free RNA probes were 
separated on 6% native PAGE and exposed to PhotoImage 
screen, then analyzed by Storm 860 scanner (Molecular 
Dynamics). 
Example 11 
Statistical Analysis 
Statistical significances based on one-way ANOVA analy 
ses were performed with Prism 5.01 software (GraphPad 
Software). 
Example 12 
Modulation of GRP7 Level and Activity Affects 
Early and Late Immune Responses 
Previous results conclusively showed that loss of GRP7 
impairs PTI and resistance to Pto DC3000 infection. To inves 
tigate the consequences of ectopic GRP7 expression, PTI and 
pathogen response was monitored in transgenic A. thaliana 
plants expressing untagged GRP7 under the control of the 
constitutive promoter 35S (GRP7ox lines; Streitner et al., 
2008, Plant J., 56:239-50). An immunoblot analysis using a 
specific anti-GRP7 antibody confirmed higher GRP7 levels 
in transgenic homozygous GRP7ox plants in comparison to 
the wild-type (WT) Col-2 ecotype (FIG. 8). A. thaliana Col-2 
(WT) and GRP7ox plants were treated with fig22, elf18, or 
chitin, which resulted in substantially higher ROS production 
in GRP7ox plants compared to WT (FIG. 1A). Similarly, 
callose deposition was increased in GRP7ox plants compared 
to WT plants after all three treatments (FIG. 1B). 
The A. thaliana GRP7ox plants were used in pathogenicity 
assays with Pto DC3000 or the Pto DC3000hrcC" mutant that 
does not secrete any T3SEs and is therefore severely hypo 
virulent. Plants were spray-inoculated and bacteria were enu 
merated at 0 and 4 days after inoculation. Interestingly, 
GRP7ox plants were more resistant to infection by Pto 
DC3000 than WT plants (FIGS. 1C and D). The Pto DC3000 
hrcC" mutant exhibited unaltered growth on GRP7ox plants. 
This may be due to the strongly reduced virulence of the Pto 
DC3000 hrcC" mutant that would require a more substantial 
improvement in plant immunity to further reduce the growth 
of this debilitated strain. The increased resistance to Pto 
DC3000 infection observed in plants over-expressing GRP7 
clearly demonstrates its important role in innate immunity. 
Example 13 
GRP7 is Required for Full Immunity to Pto DC3000 
Wt and HrcC", and HopU1 Targets GRP7 
To assess the extent to which HopU1 inhibits PTI 
responses, early and late responses triggered by flg22 were 
analyzed in transgenic A. thaliana lines constitutively 
expressing HopU1 C-terminally tagged with hemagglutinin 
(HA) under the control of the 35S promoter. In HopU1 plants, 
the ROS burst induced by flg22 and elf18 treatment was 
reduced compared to WT plants (FIGS. 9A and B). Next, it 
was confirmed that HopU1 leaves exhibit less callose depo 
sition upon flg22 treatment (FIG. 9C). These results were 
further validated using A. thaliana transgenic lines express 
ing HopU1-HA under the control of an estradiol-inducible 
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promoter (ind HopU1) (FIGS. 9D and E). Together, this 
demonstrates that HopU1 affects both early and late flg22 
induced responses. 
To test whether in planta HopU1 expression affects A. 
thaliana disease resistance, bacterial growth was assayed 
after spray-inoculation with the Pto DC3000 strains WT, 
hrcC", or AhopU1 that is hypo-virulent. HopU1 plants were 
more susceptible to all the strains tested (FIG.9F), albeit to a 
lesser extent than fls2 null mutant plants consistent with the 
reduced flg22 sensitivity of HopU1 plants (FIGS. 9A and 
C-E). These results, together with previous results, indicate 
that the abundance and/or activity of GRP7 are both required 
and limiting for triggering optimal early and late PTI 
responses. 
Example 14 
GRP7 Associates with the Immune Receptors FLS2 
and EFR at the Plasma Membrane 
The importance of GRP7 for early PTI responses suggests 
that GRP7 may affect directly PRRs and/or associated pro 
teins, or indirectly the expression and/or biogenesis of Such 
proteins. 
Notably, GRP7 was identified in an unbiased yeast two 
hybrid screen for EFR-interacting proteins (FIG. 10A). 
Importantly, this interaction was confirmed in co-immuno 
precipitation experiments after transient co-expression of 
EFR and GRP7 as C-terminally tagged fusion proteins with 
HA and enhanced green fluorescent protein (GFP) tags (EFR 
3XHA and GRP7-eciFP respectively) in Nicotiana benthami 
ana (FIG. 2A). Similarly, GRP7 and FLS2 also interacted 
when transiently co-expressed as fusion proteins (FLS2 
3xmyc and GRP7-eCFP) in N. benthamiana (FIG.2B). How 
ever, GRP7-eCFP did not interact under similar conditions 
with the LRR-RK BAK1 (BAK1-HA) (FIG.2C), which is an 
important positive regulator of PTI responses downstream of 
FLS2 and EFR. 
The GRP7-FLS2 association was confirmed by co-immu 
noprecipitation in an A. thaliana transgenic line expressing 
GRP7 C-terminally tagged with a GFP epitope (GRP7-GFP) 
under the control of the 35S promoter and using an anti-FLS2 
antibody recognizing the native FLS2 protein (FIG. 2D). The 
GRP7-FLS2 interaction occurred independently of elicita 
tion and was unaltered by flg22 treatment (FIG. 2D). The 
presence of fully glycosylated EFR and FLS2 proteins (mi 
grating at ~150 kDa and ~175 kDa, respectively) in the GRP7 
immunoprecipitates (FIGS. 2A, B and D) suggests that the 
association between GRP7 and PRRs occurs at the plasma 
membrane once the mature and functional PRRs have 
migrated through the secretory pathway. 
GRP7-GFP shows a nucleo-cytoplasmic subcellular local 
ization in A. thaliana, tobacco (Nicotiana tabacum) and N. 
benthamiana cells upon stable or transient expression (FIGS. 
11A and B). Bimolecular fluorescence complementation 
(BiFC) experiments using split-yellow fluorescent protein 
(YFP) following transient expression in N. benthamiana Sug 
gest that the GRP7-FLS2 interaction is direct (FIG. 2E). This 
interaction occurs most likely at the plasma membrane, as 
indicated by the presence of the reconstituted YFP signal in 
typical cell wall-plasma membrane connections (called 
Hechtian strands) after cell plasmolysis (arrows in FIG. 2E). 
An interaction at the plasma membrane between GRP7 and 
EFR could also be observed (FIG. 10B). 
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Example 15 
GRP7 Associates with Translational Components 
In exploratory experiments to identify GRP7 interactors in 
planta by immunoprecipitation using an A. thaliana trans 
genic line expressing GRP7 C-terminally tagged with HA 
under the control of its native promoter (GRP7-HA), several 
components of the 43S complex involved in protein transla 
tion were identified by mass-spectrometry analysis of the 
GRP7-HA immunoprecipitates (Table 8). Before the initia 
tion of active translation, the 43S complex recruits both 
mRNAS and ribosomes, and is composed of several initiation 
factors in addition to the cap-binding protein eIF4E and the 
ribosomal 40S subunit. 
Co-immunoprecipitation experiments using the A. 
thaliana GRP7-GFP transgenic line and specific antibodies 
further revealed the presence of eIF4E and the ribosomal 
subunit S14 in complex with GRP7 (FIG.3). The GRP7-GFP 
line was used here for consistency with previous targeted 
co-immunoprecipitation experiments (FIG. 2). Interestingly, 
slower-migrating bands of eIF4E were enriched in GRP7 
GFP immunoprecipitates in comparison to the main form 
detected in the input (see asterisks in FIG. 3). Strikingly, 
treatment with flg22 induced the dissociation of eIF4E and 
S14 from the GRP7 complex (FIG. 3), indicating a potential 
dynamic link between GRP7, ligand-activated PRRs and 
components of the translational machinery. 
Example 16 
HopU1 Does Not Affect Interactions Between 
GRP7, PRRs and Translational Components 
Next, it was tested whether HopU1 could directly affect 
FLS2 or the GRP7-FLS2 interaction. HopU1 did not interact 
with FLS2 in vivo as determined by co-immunoprecipitation 
and split-YFP experiments in N. benthamiana (FIG. 12A, B). 
Consistently, HopU1 did not mono-ADP-ribosylate FLS2 in 
vitro (FIG. 12C). 
Although HopU1 directly interacts with GRP7 in vivo 
(FIG. 13), HopU1 did not affect the interaction between 
GRP7 and FLS2 in an A. thaliana transgenic line expressing 
both GRP7-GFP and HopU1-HA (FIG. 4). In addition, 
HopU1 did not interfere with the association between GRP7 
GFP and eithereIF4E or S14 (FIG. 4). Therefore, the effect of 
HopU1 on PTI responses is most likely not mediated by direct 
inhibition of PRRs or protein-protein interactions with 
GRP7. 
Example 17 
GRP7 Associates with FLS2 and EFR Transcripts in 
Planta 
Next, the role of GRP7 in PTI was investigated in relation 
to its capacity to bind RNA by testing if GRP7 could bind 
PRR transcripts. Quantitative RNA-immunoprecipitation 
assays using the A. thaliana GRP7-HA transgenic line 
revealed that GRP7 binds FLS2 mRNAs in vivo indepen 
dently of flg22 treatment (FIG. 5A). As positive controls, it 
was confirmed that GRP7 binds its own transcripts as well as 
transcripts of its closest paralog GRP8 (FIG. 5A), as previ 
ously reported in vitro. GRP7 binds the 3'-UTR of its own 
transcript and of the GRP8 mRNA. Similarly, the 3'-UTR was 
identified as a binding region of GRP7 in the FLS2 mRNA 
(FIG. 5B, C). In addition to the FLS2 mRNA, GRP7 could 
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also bind the EFR transcript in vivo (FIG. 14A), consistent 
with the importance of GRP7 for responses triggered by both 
flg22 and elf18 (FIG. 1). However, transcripts of the regula 
tory LRR-RK BAK1 were not enriched in GRP7 immuno 
precipitates (FIGS. 5A and 14A), revealing a certain degree 
of specificity. Interestingly, GRP8, which is also targeted by 
HopU1, is also able to bind FLS2 and EFR mRNAs (FIG. 15). 
These results demonstrate that GRP7, as well as GRP8, bind 
transcripts of the important PRRS FLS2 and EFR. 
Example 18 
HopU1 Disrupts the Association Between GRP7 and 
PRR Transcripts 
Next, it was investigated whether HopU1 could affect the 
ability of GRP7 to bind its target mRNAs, including FLS2 
and EFR transcripts. Using an A. thaliana transgenic line 
expressing both GRP7-GFP and HopU1-HA in quantitative 
RNA-immunoprecipitation assays, it was found that the 
amount of FLS2 and EFR transcripts bound to GRP7-GFP 
was strongly reduced in the presence of HopU1 (FIGS. 6A 
and 14A). A similar effect was observed on the interaction 
between GRP7 and its own mRNA (FIGS. 6A and 14A). 
Furthermore, a GRP7(R49K) variant, which carries a muta 
tion in a conserved arginine residue within the RRM RNA 
binding domain that is mono-ADP-ribosylated by HopU1, is 
strongly impaired in its ability to bind FLS2, EFR, GRP7 and 
GRP8 transcripts (FIGS. 6B and 14B). Together, these results 
demonstrate that the mono-ADP-ribosylation of GRP7 by 
HopU1 disrupts in planta the ability of GRP7 to bind mRNAs 
of the PRRS FLS2 and EFR. 
Example 19 
HopU1 Inhibits the Pathogen-Induced FLS2 Protein 
Accumulation During Pseudomonas Infection 
Because HopU1 inhibits GRP7-FLS2 mRNA binding 
(FIG. 6), it was asked whether HopU1s action could ulti 
mately affect FLS2 protein levels after translocation into A. 
thaliana cells during Pto DC3000 infection, which would 
correspond to the most biologically-relevant observation. It 
was observed that the amount of FLS2 protein increases (3.6 
to 3.8-fold) over 24 hours in leaves infected with Pto DC3000 
hrcC' (unable to secrete any T3SEs and therefore unable to 
dampen PTI) (FIG. 7A), consistent with the previous obser 
vation that the expression of FLS2, EFR and other potential 
PRR-encoding genes is PAMP-inducible (see, for example, 
Zipfel et al., 2006, Cell, 125:749-760; and Zipfel et al., 2004, 
Nature, 428:764-767). Notably, this PAMP-induced accumu 
lation is attenuated by T3SEs (FIG. 7A: compare hrcC" with 
WT). However, this T3SE-mediated suppression was much 
less marked after inoculation with Pto DC3000 AhopU1 
(FIG. 7A: compare AhopU1 with WT). Importantly, expres 
sion of HopU1 in trans on a plasmid in Pto DC3000 AhopU1 
restored the inhibition of FLS2 accumulation during infec 
tion, while trans-complementation with the catalytically 
inactive HopU1DD variant did not (FIG. 7B). 
Notably, while the amount of cellular FLS2 mRNA 
increased during the first hours of infection with Pto DC3000 
hrcC", it decreased to a similar level upon infection with Pto 
DC3000 WT and AhopU1 (FIG. 7C). The contrasting regu 
lation and sensitivity to HopU1 of FLS2 mRNA and protein 
levels during infection further demonstrate that HopU1 regu 
lates FLS2 post-transcriptionally, while other T3SEs already 
regulate FLS2 at the transcriptional level. Consistent with 
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FLS2 being an important virulence target for HopU1, it was 
found that deletion of the flagellin-encoding gene FliC in the 
AhopU1 background (Pto DC3000 AhopU1 AfliC) suppress 
the virulence defect of Pto DC3000 AhopU1 and restore the 
virulence of Pto DC3000 AhopU1 AfliC to a comparable level 
as Pto DC3000 AfliC on WTA. thaliana plants (FIG. 7D). 
Together, these results indicate that HopU1 strongly affects 
the increased accumulation of FLS2 protein level normally 
observed during the first hours of A. thaliana infection by Pto 
DC3OOO. 
Part B 
Overexpression in Soybean 
Example 1 
Analysis of Soybean Genome 
Sequence analysis of the Soybean genome was performed 
to identify putative glycine-rich RNA binding proteins. The 
RNA-binding domain from the A. thaliana GRP7 protein was 
used as the query in the sequence analysis, and 12 Soybean 
genes were identified. See the Table below and FIG. 16. 
% sequence 
SEQID identity to 
NO A. thaliana 
(nucleic GRP7 (over 
acid, the RNA 
amino binding 
Gene Gene Name* acid) domain 
Glyma.05g00400. gmGRBP1d/GRBP1c? 15, 16 46 
GRBP1e-1 
Glyma.05g00400.2 gmGRBP1d/GRBP1c? 17, 18 46 
GRBP1e-1 
Glyma.08g26900. gmGRBP1d/GRBP1c? 19, 20 56 
GRBP1e-2 
Glyma11g36580. gmGRBP1d/GRBP1c? 21, 22 46 
GRBP1e-3 
Glyma17g08630. gmGRBP1d/GRBP1c? 23, 24 46 
GRBP1e-4 
Glyma18g00480. gmGRBP1d/GRBP1c? 25, 26 46 
GRBP1e-S 
Glyma18g00480.2 gmGRBP1d/GRBP1c? 27, 28 45 
GRBP1e-S 
Glyma18g5O150. gmGRBP1d/GRBP1c? 29, 30 58 
GRBP1e-6 
Glyma.06g01470. gmGRP7/gmORBP3a-1 31, 32 75 
Glyma11g 12480. gmGRP7/gmORBP3a-2 33, 34 81 
Glyma11g 12490. gmGRP7/gmORBP3a-3 35, 36 8O 
Glyma11g 12510.2 gmGRP7/gmORBP3a–4 37, 38 74 
from PlantGDB website 
The nucleic acid and amino acid sequence of AtGRP is 
shown in SEQID NOs: 39 & 40, respectively. 
Two of the Soybean sequences with the highest homology 
were analyzed in more detail. The putative RNA-binding 
portion of the sequence identified as Glyma(06g01470 (SEQ 
ID NO:32) was determined to have 75% sequence identity to 
the RNA-binding portion of the A. thaliana GRP7 sequence. 
In addition, the putative RNA-binding portion of the 
sequence identified as Glyma11g 12480 (SEQID NO:34) was 
determined to have 81% sequence identity to the RNA-bind 
ing portion of the A. thaliana GRP7 sequence. Significantly, 
both soybean sequences were determined to have Arginines at 
positions 47 and 49 (R47 and R49). 
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Example 2 
Transformation of Soybean and Identification of 
Transgenic Plants 
The coding sequences from the Soybean genes were cloned 
into the binary vector, pPTN200, which is a member of the 
pPZP family of binary vectors (see, for example, Hajduk 
iewicz et al., 1994, Plant Mol. Biol., 25:989-94). The soybean 
sequences were placed under control of the 35S Cauliflower 
Mosaic Virus (CaMV) promoter with a duplicated enhancer 
(Benfey & Chua, 1990, Science, 250:959-66) and terminated 
by its 3' UTR. 
The binary vector was introduced into soybean using Agro 
bacterium-mediated transformation. Specifically, the cotyle 
donary node system was used to generate transgenic soybean 
plants (see, for example, Hinchee et al., 1988, Bio/Technol. 
6:915-22). 
The pPTN200 vector carries a bar gene (Thompson et al., 
1987, EMBO, 6:2519-23) under the control of the Agrobac 
terium tumefaciens nopaline synthase promoter (Pnos) and 
terminated using the 3' UTR of the nopaline synthase gene. 
Therefore, selection of transformants was performed using 
the herbicide, Basta. 
Example 3 
Evaluating the Plants' Response to Biotic Stress 
Transgenic Soybean plants overexpressing one or more of 
the soybean sequences are exposed to PAMP and their levels 
of callose and ROS are determined as an indicator of the 
immune response. 
In addition, transgenic soybean plants overexpressing one 
or more of the Soybean sequences are challenged with a 
number of pathogens to determine the plants innate immu 
nity response. For example, the transgenic soybean plants are 
exposed to 
bacterial pathogens Such as, without limitation, 
Pseudomonas syringae pv. glycinea (bacterial blight); 
viral pathogens including, for example, tobacco ringspot 
virus (bud blight) or soybean mosaic virus (soybean 
mosaic); 
fungal pathogens such as Septoria glycines (brown spot), 
Diaporthe phaseolorum (pod and stem blight), Perono 
SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS: 4 O 
<21 Oc 
<211 
<212> 
<213> 
<22 Os 
SEO ID NO 1 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE; 
OTHER INFORMATION: oligonucleotide 
<4 OOs SEQUENCE: 1 
tgcgctgcca gataatacac tatt 
SEO ID NO 2 
LENGTH 19 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE; 
OTHER INFORMATION: oligonucleotide 
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spora manshurica (downy mildew), Phytophthora sojae 
(Phytophthora rot), Rhizoctonia Solani (Rhizoctonia 
stem rot), Sclerotinia Sclerotiorum (Sclerotinia stem 
rot), Phialophora gregata (brown stem rot), Fusarium 
Solani (Sudden death syndrome), or Macrophomina 
phaseolina (charcoal root rot). 
In addition to identifying visual indicators of pathogenicity 
(e.g., compared to a non-transgenic control plant), the pres 
ence and/or amount of one or more pathogens remaining on 
the plant is obtained (e.g., using bacterial or fungal spore 
counts or molecules techniques such as, for example, South 
ern blotting) compared to that remaining on a non-transgenic 
plant. It would be understood by those skilled in the art that 
the list of Soybean pathogens provided herein is not exhaus 
tive and is intended only to be exemplary. See, for example, 
Compendium of Soybean Diseases, 4" Ed., 1999, Hartman et 
al., eds. Amer. Phytopathol. Soc. 
The transgenic Soybean plants generally exhibit more 
resistance than non-transgenic soybean plants. 
It is to be understood that, while the methods and compo 
sitions of matter have been described herein in conjunction 
with a number of different aspects, the foregoing description 
of the various aspects is intended to illustrate and not limit the 
scope of the methods and compositions of matter. Other 
aspects, advantages, and modifications are within the scope of 
the following claims. 
Disclosed are methods and compositions that can be used 
for, can be used in conjunction with, can be used in prepara 
tion for, or are products of the disclosed methods and com 
positions. These and other materials are disclosed herein, and 
it is understood that combinations, Subsets, interactions, 
groups, etc. of these methods and compositions are disclosed. 
That is, while specific reference to each various individual 
and collective combinations and permutations of these com 
positions and methods may not be explicitly disclosed, each is 
specifically contemplated and described herein. For example, 
if a particular composition of matter or a particular method is 
disclosed and discussed and a number of compositions or 
methods are discussed, each and every combination and per 
mutation of the compositions and the methods are specifically 
contemplated unless specifically indicated to the contrary. 
Likewise, any Subset or combination of these is also specifi 
cally contemplated and disclosed. 
24 
21 
<4 OOs, SEQUENCE: 2 
tgctg.cccaa cat caggtt 
<210s, SEQ ID NO 3 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 3 
actict cct Co aggggctaag gat 
<210s, SEQ ID NO 4 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 4 
agctaa.ca.gc tict coaggga tigg 
<210s, SEQ ID NO 5 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
< 4 OO SEQUENCE: 5 
cggatgaagc agtacgagaa 
<210s, SEQ ID NO 6 
&211s LENGTH: 21 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 6 
c cattcctgaggagaactitt g 
<210s, SEQ ID NO 7 
&211s LENGTH: 24 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OO > SEQUENCE: 7 
accocctic ct atctot cota cacc 
<210s, SEQ ID NO 8 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 8 
Ctgggit cotc titcagctggit aca 
<210s, SEQ ID NO 9 
&211s LENGTH: 25 
US 9, 169,489 B2 
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19 
23 
23 
21 
24 
23 
22 
23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 9 
tgatgacaga gct Cttgaga Ctgcc 
<210s, SEQ ID NO 10 
&211s LENGTH: 31 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 10 
t cct cotcca ccct cqcgtc taccgc.cgcc a 
<210s, SEQ ID NO 11 
&211s LENGTH: 25 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 11 
Caatgatgaa gat Cttcaaa ggacg 
<210s, SEQ ID NO 12 
&211s LENGTH: 33 
& 212 TYPE DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 12 
citcgtaacca ccaccgcct c ctic ct gagta t co 
<210s, SEQ ID NO 13 
&211s LENGTH: 27 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 13 
gatggit accg aagtttagca gcaaagc 
<210s, SEQ ID NO 14 
&211s LENGTH: 29 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: oligonucleotide 
<4 OOs, SEQUENCE: 14 
gagctcqagg ttcatcaaaa ccaaatttic 
<210s, SEQ ID NO 15 
&211s LENGTH: 825 
&212s. TYPE: DNA 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 15 
atggctttct ttggtagaat tgaattta ttalagacaga 
US 9, 169,489 B2 
- Continued 
Cagcaa.gcag gcaggittagt 
25 
31 
25 
33 
27 
29 
6 O 
24 
t cagaattgc 
agcacaaagc 
gctttittcaa 
agat.ccagag 
Caggccttgg 
agacct cqtg 
tatgaaggtg 
gggagtggitt 
ggct Ctggca 
gaaagcticta 
ggtgcaggta 
ggcagcagtg 
tacagggatg 
<210s, SEQ I 
&211s LENGT 
212. TYPE : 
&213s ORGAN 
gat catcc cc 
tgtttatcgg 
aatatggtga 
gatttggctt 
atggtcagga 
gatatggtgg 
gtagcagcta 
atggatatgg 
atalactatto 
ctggttittgc 
gtggCactag 
gccaattaga 
acaacgatgc 
D NO 16 
H: 274 
PRT 
25 
titcgttttitt 
aggtgttt Ca 
agttgttgat 
tattacatac 
cct acatggit 
cggtggctitt 
tcgtggtggit 
tggaggcagg 
aggaggct at 
Cagtaatgga 
ctittgctgat 
tagcaaag.ca 
agatgattitt 
ISM: Glycine max 
<4 OOs, SEQUENCE: 16 
Met Ala Phe 
1. 
Arg Glin Val 
Ile Arg Ser 
35 
Val Ser Tyr 
SO 
Tyr Gly Glu 
65 
Arg Ser Arg 
Ser Ser Ala 
Ile Arg Val 
115 
Gly Phe Gly 
13 O 
Ser Ser Tyr 
145 
Gly Ser Gly 
Asn Ala Gly 
195 
Asn Gly Tyr 
21 O 
Gly. Thir Ser 
225 
Phe Gly Arg Ile Gly 
5 
Ser Ser Glu Lieu. Arg 
Met Ser Ser Ala Pro 
4 O 
Ser Thr Asp Glu Glin 
55 
Val Val Asp Ala Arg 
70 
Gly Phe Gly Phe Ile 
85 
Ile Glin Ala Lieu. Asp 
Asn Tyr Ala Asn. Glu 
12 O 
Ser Tyr Gly Ala Val 
135 
Arg Gly Gly Tyr Gly 
150 
Tyr Gly Tyr Gly Gly 
1.65 
Ser Gly Ser Gly Asn 
18O 
Gly Val Gly Asn His 
Asp Gly Ser Val Val 
215 
Phe Ala Asp Gly Tyr 
23 O 
caggctatac 
tatt c tactg 
gctaggataa 
actitcggttg 
cgc.ccgatta 
ggttcatacg 
tatggtggtg 
tatggat cag 
gctggtaatg 
tatgatggaa 
ggctatgatg 
agcagcaaag 
gcc aagaggg 
Asn Lieu. Luell 
1O 
Ser Ser Pro 
25 
Ser Thr Lys 
Ser Lieu. Arg 
Ile Ile Met 
7s 
Thr Tyr Thr 
90 
Gly Glin Asp 
105 
Arg Pro Arg 
Gly Gly Gly 
Gly Asp Asn 
155 
Gly Arg Tyr 
17O 
Asn Tyr Ser 
185 
Glu Ser Ser 
Asp Gly Gly 
Asp Gly Ser 
235 
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gcagtatgtc. 
acgagcaaag 
titatggat.cg 
aggaggcatc 
gggtgaatta 
gtgctgtagg 
acaactatag 
gcggcaatta 
CC9gtggtgt 
gtgttgttgga 
galagtgcggg 
gagatgagga 
cittga 
Arg Glin Thr 
Ser Phe Phe 
3O 
Leul Phe Ile 
45 
Glu Ala Phe 
6 O 
Asp Arg Glu 
Ser Wall Glu 
Lieu. His Gly 
11 O 
Gly Tyr Gly 
125 
Gly Tyr Glu 
14 O 
Tyr Ser Arg 
Gly Ser Gly 
Gly Gly Tyr 
19 O 
Thr Gly Phe 
2O5 
Val Gly Ala 
22O 
Ala Gly Ser 
atctgct coa 
tittgagggaa 
tgaaactggit 
aagtgcc att 
tgctaatgaa 
tgg.cggtggc 
tcqaaatgat 
tggggacagt 
aggcaat cat 
tggtggtgtt 
gtctgaattit 
ttittggtgat 
Ala Ser 
15 
Glin Ala 
Gly Gly 
Ser Lys 
Thr Gly 
Glu Ala 
95 
Arg Pro 
Gly Gly 
Gly Gly 
Asn Asp 
160 
Gly Asn 
17s 
Ala Gly 
Ala Ser 
Gly Ser 
Glu Phe 
24 O 
12 O 
18O 
24 O 
3OO 
360 
54 O 
660 
72 O 
825 
26 
US 9, 169,489 B2 
27 
- Continued 
Gly Ser Ser Gly Glin Lieu. Asp Ser Lys Ala Ser Ser Lys Gly Asp Glu 
245 250 255 
Asp Phe Gly Asp Tyr Arg Asp Asp Asn Asp Ala Asp Asp Phe Ala Lys 
26 O 265 27 O 
Arg Ala 
<210s, SEQ ID NO 17 
&211s LENGTH: 738 
&212s. TYPE: DNA 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 17 
atggctttct ttggtagaat tgaattta ttalagacaga cagcaa.gcag gCaggittagt 6 O 
t cagaattgc gat catcc cc titcgttttitt caggctatac gcagtatgtc atctgct coa 12 O 
agcacaaagc tigtttatcgg aggtgttt ca tatt Ctactg acgagcaaag tittgagggaa 18O 
gctttittcaa aatatggtga agttgttgat gctaggataa titatggat.cg tdaaactggit 24 O 
agat.ccagag gatttggctt tattacatac actitcggttg aggaggcatc aagtgcc att 3OO 
Caggccttgg atggtcagga cct acatggit cqc cc.gatta gggtgaatta totaatgaa 360 
agacct cqtg gatatggtgg C9gtggctitt ggttcatacg gtgctgtagg togcggtggc 42O 
tatgaaggtg gtagcagcta t cqtggtggit tatggtggtg acaactatag ticgaaatgat 48O 
gggagtggitt atggatatgg taggcaat catgaaagct Ctactggttt to cagtaat 54 O 
ggatatgatg gaagttgttgt ggatggtggit gttggtgcag gtagtggcac tagctittgct 6OO 
gatggctatg atggaagtgc ggggtctgaa tttgg Cagca gtggcCaatt agatagcaaa 660 
gcaa.gcagca aaggagatga ggattittggit gattacaggg atgacaacga tigcagatgat 72 O 
tittgccaaga gggcttga 738 
<210s, SEQ ID NO 18 
&211s LENGTH: 245 
212. TYPE: PRT 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 18 
Met Ala Phe Phe Gly Arg Ile Gly Asn Lieu. Lieu. Arg Glin Thr Ala Ser 
1. 5 1O 15 
Arg Glin Val Ser Ser Glu Lieu. Arg Ser Ser Pro Ser Phe Phe Glin Ala 
2O 25 3O 
Ile Arg Ser Met Ser Ser Ala Pro Ser Thr Lys Lieu Phe Ile Gly Gly 
35 4 O 45 
Val Ser Tyr Ser Thr Asp Glu Glin Ser Lieu. Arg Glu Ala Phe Ser Lys 
SO 55 6 O 
Tyr Gly Glu Val Val Asp Ala Arg Ile Ile Met Asp Arg Glu Thr Gly 
65 70 7s 8O 
Arg Ser Arg Gly Phe Gly Phe Ile Thr Tyr Thr Ser Val Glu Glu Ala 
85 90 95 
Ser Ser Ala Ile Glin Ala Lieu. Asp Gly Glin Asp Lieu. His Gly Arg Pro 
1OO 105 11 O 
Ile Arg Val Asn Tyr Ala Asn. Glu Arg Pro Arg Gly Tyr Gly Gly Gly 
115 12 O 125 
Gly Phe Gly Ser Tyr Gly Ala Val Gly Gly Gly Gly Tyr Glu Gly Gly 
13 O 135 14 O 
Ser Ser Tyr Arg Gly Gly Tyr Gly Gly Asp Asn Tyr Ser Arg Asn Asp 
145 150 155 160 
28 
Gly 
Phe 
Ala 
Ser 
Gly 
225 
Phe 
Ser 
Ala 
Gly 
Glu 
21 O 
Asp 
Ala 
29 
Gly Tyr Gly Tyr Gly Gly 
1.65 
Ser Asn Gly Tyr Asp Gly 
18O 
Ser Gly. Thir Ser Phe Ala 
195 
Phe Gly Ser Ser Gly Glin 
215 
Glu Asp Phe Gly Asp Tyr 
23 O 
Lys Arg Ala 
245 
<210s, SEQ ID NO 19 
&211s LENGTH: 738 
&212s. TYPE: DNA 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 19 
atggcgttct taaataaaat 
caagatttitt cagtgtctac 
aagcttitttgtcggaggt at 
gct cqctatg gagaagtaat 
agaggttittg gct tcataac 
atggatggtc aggat.ctt.ca 
cgtcCagggit ttggtggtga 
aggggtggala act atggagg 
alactatggaa gtggcaatta 
agttacacta gtggtgctaa 
tittggcticag ctagoggtga 
gatgaattica ttgagccact 
tacgct caga accgctga 
<210s, SEQ ID NO 2 O 
&211s LENGTH: 245 
212. TYPE: PRT 
&213s ORGANISM: 
<4 OOs, SEQUENCE: 2O 
tggaaatctg 
CCC at CaCtt 
ttcttacago 
agatgtcaag 
ttittgcaa.ca 
tggtc.gcagg 
tggtggat at 
tggatataac 
taatgttaca 
tgctggtaat 
att cagoagc 
tgaagacaat 
Glycine max 
Met Ala Phe Lieu. Asn Lys Ile Gly 
1. 
Lys 
Ala 
Glu 
65 
Arg 
His 
Ile 
Ser 
SO 
Wall 
Gly 
5 
Ile Asin Glin Asp Phe Ser 
Arg Ser Met Ser Ser Ala 
35 4 O 
Thir Asp Asp Met Ser Lieu. 
55 
Ile Asp Val Llys Val Ile 
70 
Phe Gly Phe Ile Thr Phe 
85 
Gly Asn His 
17O 
Ser Wal Wall 
185 
Asp Gly Tyr 
Lieu. Asp Ser 
Arg Asp Asp 
235 
gtcaagaatt 
titccaa.gcaa 
actgatgata 
gtc attatgg 
agtgaggatg 
atacgggtga 
agggg.ca.gtg 
agtggcagcg 
agcagctata 
taccalattica 
aac caaaatg 
gtgagggaga 
Asn Lieu Wall 
1O 
Wall Ser Thr 
25 
Llys Lieu. Phe 
Arg Glu Ser 
Met Asp Arg 
7s 
Ala Thir Ser 
90 
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Glu 
Asp 
Asp 
Lys 
22O 
Asn 
Ser 
Gly 
Gly 
Ala 
Asp 
Ser 
Gly 
19 O 
Ser 
Ser 
Ala 
ctgctgtcaa 
ttagatc cat 
tgagtttgcg 
atcgtgaaac 
catcttctgc 
attatgctac 
gtggCagcga 
atggctacaa 
gtgatggcaa. 
atgaaaattic 
acgcaac agg 
acaatgatga 
Pro 
Wall 
Phe 
6 O 
Glu 
Glu 
Asn 
Ser 
Gly 
45 
Ala 
Thir 
Asp 
Ser 
Luell 
Gly 
Arg 
Gly 
Ala 
Thr Gly 
17s 
Val Gly 
Ala Gly 
Ser Lys 
Asp Asp 
24 O 
gcacatcaat 
gtcatctgca 
agagt cittitt 
tggcagg to a 
cattcagggc 
agaaagg to a 
tggctacaat 
taggggtgga 
tgctgaaact 
tggtggagtt 
tgcagacaat 
acc tactgac 
Ala Wall 
15 
Phe Glin 
Ile Ser 
Arg Ser 
8O 
Ser Ser 
95 
6 O 
12 O 
18O 
24 O 
3OO 
360 
54 O 
660 
72 O 
738 
30 
Ala 
Wall 
Gly 
Tyr 
145 
Asn 
Asn 
Phe 
Ser 
Glu 
225 
< 4 OO 
Ile 
Asn 
Tyr 
13 O 
Gly 
Ala 
Asn 
Ser 
21 O 
Pro 
Ala 
Glin 
Tyr 
115 
Arg 
Gly 
Gly 
Glu 
Glu 
195 
Asn 
Luell 
Glin 
31 
Gly Met Asp Gly Glin 
Ala Thr Glu Arg Ser 
12 O 
Gly Ser Gly Gly Ser 
135 
Gly Tyr Asn Ser Gly 
150 
Ser Gly Asn Tyr Asn 
1.65 
Thir Ser Tyr Thr ser 
18O 
Asn Ser Gly Gly Val 
Glin Asn Asp Ala Thr 
215 
Glu Asp Asn Val Arg 
23 O 
Asn Arg 
245 
SEQ ID NO 21 
LENGTH: 438 
TYPE: DNA 
ORGANISM: Glycine max 
SEQUENCE: 21 
atggccttct gtaataaggt 
gcacctgttt 
ggaggc ctitt 
gatgtggttg 
tttgtcaact 
atgggcgaag 
catccatgct 
catatggagt 
atgcaaaagt 
t ct coaatga 
Cattagggta 
tggtggittat 
cgcaatggtg gttggtga 
<210s, SEQ ID NO 22 
&211s LENGTH: 145 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 22 
tggaaatgtc. 
taattacatt 
tgacgatcag 
tataactgac 
tgagt ctgca 
tcc tatgcaa 
cgcagtgggg 
Glycine max 
Met Ala Phe Cys Asn Llys Val Gly 
1. 
Arg 
Met 
Asp 
Ala 
65 
Phe 
Ser 
Ser 
Glin 
SO 
Wall 
Thir 
Ser 
35 
Ser 
Wall 
Asn 
5 
Glin Ala Pro Wal Ser 
Ser Llys Lieu. Phe Ile 
4 O 
Lieu Lys Asp Ala Phe 
55 
Ile Thr Asp Arg Asp 
70 
Phe Ser Asn Asp Glu 
85 
Asp Lieu. His 
105 
Arg Pro Gly 
Asp Gly Tyr 
Ser Asp Gly 
155 
Wall. Thir Ser 
17O 
Gly Ala Asn 
185 
Phe Gly Ser 
Gly Ala Asp 
Glu Asn. Asn 
235 
ttgaggc agg 
cgctgcatgt 
t ct cittaagg 
agagactictg 
agttcggcac 
atgatagacic 
gttittggcgg 
Asn. Wall Lieu. 
1O 
Ser Met Leu 
25 
Gly Gly Lieu. 
Ser Gly Phe 
Ser Gly Arg 
7s 
Ser Ala Ser 
90 
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Gly Arg Arg 
Phe 
Asn 
14 O 
Ser 
Ala 
Ala 
Asn 
22O 
Asp 
Gly 
125 
Arg 
Asn 
Gly 
Ser 
2O5 
Asp 
Glu 
11 O 
Gly 
Gly 
Arg 
Ser 
Asn 
19 O 
Gly 
Glu 
Pro 
cittcaa.gcaa 
atgcatttitc 
gaagatcaag 
t citctgcaat 
ttctggacct 
cgggtggtga 
Arg 
Asn 
Ser 
Gly 
6 O 
Ser 
Ser 
Glin 
Tyr 
45 
Asp 
Arg 
Ala 
Gly 
Ile 
Gly 
Wall 
Gly 
Luell 
Ile Arg 
Asp Gly 
Gly Asn 
Gly Gly 
160 
Asp Gly 
17s 
Tyr Glin 
Glu Phe 
Phe Ile 
Thir Asp 
24 O 
cagcacacaa 
gctttittatt 
tggctttgga 
gggatttgga 
ggatgggaag 
Caatctggcg 
ttttgcttct 
Ala Ala 
15 
Arg Cys 
Val Asp 
Val Asp 
Phe Gly 
Ser Ala 
95 
6 O 
12 O 
18O 
24 O 
3OO 
360 
438 
32 
Met 
33 
Asp Gly Lys Met Gly Glu Ala Lieu. Gly Tyr 
105 
Asp Lieu. Lieu. Asp Lieu. Asn Lieu Ala Ala Ala Ala 
Wall 
Trp 
145 
115 12 O 
Gly Val Lieu Ala Ala Gly Gly Asp Phe Ala 
13 O 
<210s, SEQ ID NO 23 
&211s LENGTH: 828 
&212s. TYPE: DNA 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 23 
atggctttct ttggtagaat 
tcaaaattgc 
agcacaaaac 
gctttittcaa 
agat.ccagag 
Caggccttgg 
agacct cqtg 
ggtggittatg 
ggtggcaact 
t caggcggca 
agta acagtg 
tittgc.cggta 
tittggcagca 
gttcgcc.ccc 
tgtttattgg 
aatatggtga 
gatttggctt 
atggtcagga 
gatatggtgg 
alaggtggtgg 
at agtcgaaa 
attatgggga 
gacattttgg 
atggatatga 
gtggccalatt 
gattacaggg atgacaacga 
<210s, SEQ ID NO 24 
&211s LENGTH: 275 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 24 
135 
tgggaatttg 
tt catttitt t 
aggtgttt Ca 
agttgttgat 
tattacatac 
tott catggit 
tggtggcggc 
tggcagcggt 
tgatgggggt 
Cagtggcc ct 
tgatgc.cggit 
tggaagtgtc. 
agatagcaaa 
tgcagataat 
Glycine max 
Met Ala Phe Phe Gly Arg Ile Gly 
1. 
Arg 
Ile 
Wall 
Tyr 
65 
Arg 
Ser 
Ile 
Glin 
Arg 
Ser 
SO 
Gly 
Ser 
Ser 
Arg 
Wall 
Cys 
35 
Glu 
Arg 
Ala 
Wall 
5 
Ser Ser Llys Lieu. Arg 
Met Ser Ser Ala Pro 
4 O 
Ser Thr Asp Glu Glin 
55 
Val Val Asp Ala Arg 
70 
Gly Phe Gly Phe Ile 
85 
Ile Glin Ala Lieu. Asp 
Asn Tyr Ala Asn. Glu 
ttacgacaga 
caggctatac 
tatt c tactg 
gct cqgataa 
actitcggttg 
cgc.ccaatta 
ggctittggitt 
tat cqtggaa 
ggittatggat 
ggcaataact 
agtgtaggca 
gtggatggcg 
acalagcagca 
tittgccaaga 
Asn Lieu. Luell 
1O 
Ser Pro Pro 
25 
Ser Thr Lys 
Ser Lieu. Arg 
Ile Ile Met 
7s 
Thr Tyr Thr 
90 
Gly Glin Asp 
105 
Arg Pro Arg 
US 9, 169,489 B2 
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Pro 
Wall 
Met 
Wall 
125 
Glin 
11 O 
Wall 
Ser Arg Asn 
14 O 
Cagcgagcag 
gctgtatgtc. 
acgagcaaag 
titatggat.cg 
aggaggcatc 
gggtgaatta 
catatggtgc 
atgtttctga 
atggtgcagg 
acticgggagg 
atcatgaaag 
atggagatga 
gggcttga 
Arg 
Ser 
Lell 
Glu 
6 O 
Asp 
Ser 
Lell 
Gly 
Glin 
Phe 
Phe 
45 
Ala 
Arg 
Wall 
His 
Thir 
Phe 
3O 
Ile 
Phe 
Glu 
Glu 
Gly 
11 O 
Gly 
Met Ile 
Ile Ala 
Gly Gly 
gCaggittagt 
atctg.ccc.ca 
Cttgagggaa 
tgaaactggit 
aagtgcc att 
tgctaatgaa 
tgtaggtggc 
tggittatggit 
Cagittatgga 
Ctatagtggit 
ctic tactggit 
agggit C9gaa 
gggttittggg 
Ala Ser 
15 
Glin Ala 
Gly Gly 
Ser Lys 
Thr Gly 
8O 
Glu Ala 
95 
Arg Pro 
Gly Gly 
6 O 
12 O 
18O 
24 O 
3OO 
360 
54 O 
660 
72 O 
828 
34 
Gly 
Gly 
145 
Gly 
Gly 
Asn 
Ala 
Gly 
225 
Phe 
Glu 
< 4 OOs 
Gly 
13 O 
Gly 
Gly 
Ser 
Gly 
21 O 
Gly 
Gly 
Arg 
115 
Gly 
Gly 
Asn 
Ser 
195 
Ser 
Asp 
Ser 
Phe 
Ala 
27s 
35 
12 O 
Phe Gly Ser Tyr Gly 
135 
Gly Ser Gly Tyr Arg 
150 
Tyr Ser Arg Asn Asp 
1.65 
Gly Ser Gly Gly Asn 
18O 
Gly Gly Tyr Ser Gly 
Val Gly Asn His Glu 
215 
Gly Ser Val Val Asp 
23 O 
Ser Gly Glin Lieu. Asp 
245 
Gly Asp Tyr Arg Asp 
26 O 
SEO ID NO 25 
LENGTH: 432 
TYPE: DNA 
ORGANISM: Glycine max 
SEQUENCE: 25 
atggcgttct gtaataaggt 
gcc cctgttg 
ggaggc ctitt 
gatgtggttg 
tttgtcaact 
gatctaaatg 
cgt.ccatgct 
catatggagt 
atgcaaaagt 
t ct coaatga 
ggc galagcat 
gtggcggitta 
ggtggttggt ga 
<210s, SEQ ID NO 26 
&211s LENGTH: 143 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 26 
tggaaatgtc. 
taattacatc. 
tgatgaccag 
tataactgat 
tgagt ctgca 
tcgggitat co 
Glycine max 
Met Ala Phe Cys Asn Llys Val Gly 
1. 
Arg 
Met 
Asp 
Ala 
65 
Ser 
Ser 
Glin 
SO 
Thir 
Ser 
35 
Ser 
Wall 
5 
His Ala Pro Wall Ala 
Ser Llys Lieu. Phe Ile 
4 O 
Lieu Lys Asp Ala Phe 
55 
Ile Thr Asp Arg Asp 
70 
Ala Val Gly 
Gly Asn Val 
155 
Gly Gly Gly 
17O 
Tyr Gly Asp 
185 
Ser Asn. Ser 
Ser Ser Thr 
Gly Gly Val 
235 
Ser Lys Thr 
250 
Asp Asn Asp 
265 
ttgaggc agg 
cgctgcatgt 
t ct cittaagg 
agaga cagtg 
agttcggcac 
tatgcaaatg 
gattatgatg 
Asn. Wall Lieu. 
1O 
Ser Met Leu 
25 
Gly Gly Lieu. 
Ser Gly Phe 
Ser Gly Arg 
7s 
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Gly 
14 O 
Ser 
Ser 
Gly 
Gly 
22O 
Gly 
Ser 
Ala 
125 
Gly 
Asp 
Gly 
Gly 
His 
Phe 
Ala 
Ser 
Asp 
Gly 
Gly 
Pro 
19 O 
Phe 
Ala 
Gly 
Asn 
Asn 
27 O 
cittcaa.gcaa 
atgcatttitc 
gaagatcaag 
t citctgcaat 
ataalaccatc. 
gtgattittgc 
Arg 
Asn 
Ser 
Gly 
6 O 
Ser 
Glin 
Tyr 
45 
Asp 
Arg 
Gly 
Ile 
Gly 
Wall 
Gly 
Tyr Glu 
160 
Gly Ala 
17s 
Gly Asn 
Gly Asp 
Gly Asn 
Ser Glu 
24 O 
Gly Asp 
255 
Phe Ala 
cagcacacat 
gcttitt catt 
tggctttgga 
gggatttgga 
ggacgggaag 
tgcacct cqa 
ttct cqtagt 
Ala Ala 
15 
Arg Cys 
Val Asp 
Val Asp 
Phe Gly 
8O 
6 O 
12 O 
18O 
24 O 
3OO 
360 
432 
36 
37 
Phe Val Asin Phe Ser Asn Asp Glu 
85 
Met Asp Gly Lys Asp Lieu. Asn Gly 
Asn Asp Llys Pro Ser Ala Pro Arg 
115 12 O 
Gly Gly Asp Tyr Asp Gly Asp Phe 
13 O 
<210s, SEQ ID NO 27 
&211s LENGTH: 426 
&212s. TYPE: DNA 
135 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 27 
atggcgttct gtaataaggt 
gcc cct gttg cqtccatgct 
ggaggc ctitt catatggagt 
gatgtggttg atgttataac 
aactitcticca atgatgagtic 
aatgggcgaa gcattcgggit 
ggcggtggcg gttatcgtgg 
tggtga 
<210s, SEQ ID NO 28 
&211s LENGTH: 141 
212. TYPE: PRT 
tggaaatgtc. 
taattacatc. 
tgatgaccag 
tgatagagac 
tgcaagttcg 
atcc tatgca 
cggggatt at 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 28 
Met Ala Phe Cys Asn Llys Val Gly 
1. 5 
Arg Ser Thr His Ala Pro Val Ala 
Met Ser Ser Ser Lys Lieu Phe Ile 
35 4 O 
Asp Glin Ser Lieu Lys Asp Ala Phe 
SO 55 
Val Ile Thir Asp Arg Asp Ser Gly 
65 70 
Asn Phe Ser Asn Asp Glu Ser Ala 
85 
Gly Lys Asp Lieu. Asn Gly Arg Ser 
Llys Pro Ser Ala Pro Arg Pro Gly 
115 12 O 
Asp Tyr Asp Gly Asp Phe Ala Ser 
13 O 
<210s, SEQ ID NO 29 
&211s LENGTH: 735 
&212s. TYPE: DNA 
135 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 29 
Ser Ala Ser 
90 
Arg Ser Ile 
105 
Pro Gly Gly 
Ala Ser Arg 
ttgaggc agg 
cgctgcatgt 
t ct cittaagg 
agtggaagat 
gcact citctg 
aatgataaac 
gatggtgatt 
Asn. Wall Lieu. 
1O 
Ser Met Leu 
25 
Gly Gly Lieu. 
Ser Gly Phe 
Arg Ser Arg 
7s 
Ser Ser Ala 
90 
Ile Arg Val 
105 
Gly Gly Gly 
Arg Ser Gly 
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Ser 
Arg 
Gly 
Ser 
14 O 
Ala 
Wall 
Gly 
125 
Gly 
Luell 
Ser 
11 O 
Gly 
Gly 
cittcaa.gcaa 
atgcatttitc 
Caaggggatt 
Caatggacgg 
catctgcacc 
ttgcttctic g 
Arg 
Asn 
Ser 
Gly 
6 O 
Gly 
Lell 
Ser 
Gly 
Gly 
14 O 
Glin 
Tyr 
45 
Asp 
Phe 
Ser 
Tyr 
125 
Trp 
Gly 
Ile 
Gly 
Wall 
Gly 
Ala 
Ala 
11 O 
Arg 
Ser Ala 
95 
Tyr Ala 
Tyr Arg 
Trp 
cagcacacat 
gcttitt catt 
tggctttgga 
tggatttgtc. 
gaaggat.cta 
tcgacctggit 
tagtggtggit 
Ala Ala 
15 
Arg Cys 
Val Asp 
Val Asp 
Phe Wall 
8O 
Met Asp 
95 
Asn Asp 
Gly Gly 
6 O 
12 O 
18O 
24 O 
3OO 
360 
426 
38 
atggcgttct 
caggatttitt 
aagcttitt cq 
gct cqctatg 
agaggttittg 
atggatggcc 
cgtcCagggit 
ggaalactatg 
tatggaagtg 
tacactggtg 
ggct cagcta 
gaatt cattg 
gct Cagaacc 
<210s, SEQ I 
&211s LENGT 
212. TYPE : 
taaataaaat 
cggcgt.ctac 
tcggaggt at 
gagaagtaat 
gctttgtaac 
aggat.ctt.ca 
ttggtggtga 
galagtggagg 
gcggittataa 
gtggtaatgc 
gcggtgaatt 
agccacttga 
gctga 
D NO 3 O 
H: 244 
PRT 
39 
tggaaatctg 
c cott cact t 
ttcttacago 
tgatggcaag 
ttittgcaa.ca 
tggtcggagg 
tggtggat at 
tggatatggit 
tgttactago 
tag taattac 
Cagcagcaac 
agacaatgtg 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 30 
Met Ala Phe 
1. 
Llys His Ile 
Ala Ile Arg 
35 
Tyr Ser Thr 
SO 
Glu Wall Ile 
65 
Arg Gly Phe 
Ala Ile Glin 
Val Asn Tyr 
115 
Gly Tyr Gly 
13 O 
Ser Gly Gly 
145 
Tyr Gly Ser 
Ala Glu Thir 
ASn Glu Asn 
195 
Ser Asn. Glin 
21 O 
Pro Lieu. Glu 
225 
Lieu. Asn Lys Ile Gly 
5 
Asin Glin Asp Phe Ser 
Ser Met Ser Ser Ala 
4 O 
Asp Asp Met Ser Lieu. 
55 
Asp Gly Llys Val Ile 
70 
Gly Phe Val Thr Phe 
85 
Gly Met Asp Gly Glin 
Ala Thr Glu Arg Ser 
12 O 
Ser Gly Gly Gly Gly 
135 
Gly Tyr Gly Gly Gly 
150 
Gly Gly Tyr Asn Val 
1.65 
Ser Tyr Thr Gly Gly 
18O 
Ser Gly Gly Asp Phe 
Asn Asp Thr Ala Gly 
215 
Asp Asn Val Arg Glu 
23 O 
citcaagaatt 
titccaa.gcaa 
actgatgata 
gtt attatgg 
agtgaggatg 
atacgggtga 
ggcagtggtg 
ggtggtggtg 
agctatagtg 
caattcaatg 
caaaatgaca 
agggaga aca 
Asn Lieu. Luell 
1O 
Ala Ser Thr 
25 
Llys Lieu. Phe 
Arg Glu Ser 
Met Asp Arg 
7s 
Ala Thir Ser 
90 
Asp Lieu. His 
105 
Arg Pro Gly 
Tyr Asn Gly 
Gly Gly Tyr 
155 
Thir Ser Ser 
17O 
Gly Asn Ala 
185 
Gly Ser Ala 
Ala Asp Asn 
Asn Asn Asp 
235 
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ctgctgtcaa goa catcaat 
ttagatc cat 
tgagtttgcg 
atcgtgaaac 
catcttctgc 
attatgctac 
gtggtggcta 
gctataatag 
gtggcaatgc 
aaaactctgg 
Cagcaggtgc 
atgatggacc 
Pro 
Wall 
Phe 
6 O 
Glu 
Glu 
Gly 
Phe 
Gly 
14 O 
Asn 
Ser 
Ser 
Asp 
22O 
Gly 
Asn 
Ser 
Gly 
45 
Ala 
Thir 
Asp 
Arg 
Gly 
125 
Gly 
Arg 
Ser 
Asn 
Gly 
2O5 
Glu 
Pro 
Ser 
Luell 
Gly 
Arg 
Gly 
Ala 
Arg 
11 O 
Gly 
Asn 
Gly 
Gly 
Tyr 
19 O 
Glu 
Phe 
Thir 
gtcatctgca 
agagt cittitt 
tggcagg to a 
cattcagggc 
agaaagg to a 
Caatgggggt 
gggtggaaac 
tgaaact agt 
tggagattitt 
agacaatgat 
taccgacitac 
Ala Wall 
15 
Phe Glin 
Ile Ser 
Arg Ser 
8O 
Ser Ser 
95 
Ile Arg 
Asp Gly 
Gly Asn 
160 
Gly Asn 
17s 
Glin Phe 
Phe Ser 
Ile Glu 
Asp Tyr 
24 O 
6 O 
12 O 
18O 
24 O 
3OO 
360 
54 O 
660 
72 O 
73 
40 


cggagaaact ag 
<210s, SEQ ID NO 36 
&211s LENGTH: 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 
Met Leu Ser Met 
1. 
Gly 
His 
Gly 
Met 
65 
Asn 
Gly 
Gly 
Ser 
Luell 
Ile 
Gly 
Gly 
Arg 
13 O 
Ala 
Gly 
35 
Ser 
Asp 
Thir 
Arg 
Gly 
115 
Trp 
Asn 
Arg 
Ala 
Wall 
Arg 
Tyr 
Ser 
143 
45 
Glycine max 
36 
Asn 
85 
Glu 
Gly 
Arg 
<210s, SEQ ID NO 37 
&211s LENGTH: 
&212s. TYPE: DNA 
<213> ORGANISM: Glycine max 
<4 OOs, SEQUENCE: 
408 
37 
Ser Ala Tyr 
Thir Asp Asp 
Wall Glu Ser 
4 O 
Phe Gly Phe 
55 
Glu Gly Met 
70 
Glu Ala Glin 
Gly Gly Tyr 
Gly Asp Arg 
12 O 
Gly Gly Asp 
135 
atggct tctg. Cagatgttga gttcc.gttgc 
aacgatgc cc 
aacgaccgtg 
t caatgaaag 
gtcaacgaag 
ggtggaggat 
tctcgcggtg 
< 4 OOs 
tcq agaaag.c ctitttcaatc 
agactggaag gtc.ca.gagga 
atgcgatcgc aggaatgaac 
Ctcagacccd cqc.ca.gc.cgt. 
acggcggtgg tagaga.ccgt 
gggaaggcgg tdgat CC9at 
PRT 
SEQUENCE: 
SEQ ID NO 38 
LENGTH: 
TYPE : 
ORGANISM: Glycine max 
135 
38 
Met Ala Ser Ala Asp 
1. 5 
Wall Glu Phe 
Wall Glu 
1O 
His Ala 
25 
Lys Ile 
Wall. Thir 
Asin Gly 
Ser Arg 
90 
Asn Arg 
105 
Asp Cys 
Wall Asn 
Tyr 
Luell 
Ile 
Phe 
Glin 
Gly 
Gly 
Gly 
Gly 
tttgttggtg 
tacggcgaca 
titcggatttg 
ggcCagg acc 
ggittacggtg 
ggaaactgga 
Arg Cys 
1O 
Phe 
Trp Val Thr Gly Asn Asp Ala Lieu. Glu Lys Ala 
Asp Ile Val Glu Ser 
35 
Arg Gly Phe Gly Phe 
SO 
Llys Val Ile 
4 O 
Wall. Thir Phe 
55 
25 
Asn Asp 
Ala Ser 
Arg 
Glu 
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Arg 
Glu 
Asn 
Ala 
6 O 
Asn 
Ser 
Gly 
Ser 
14 O 
Asp 
45 
Ser 
Lell 
Arg 
Gly 
Gly 
125 
Arg 
Phe 
Ala 
Arg 
Glu 
Asp 
Gly 
Gly 
11 O 
Asp 
Arg 
ggcttgcttg 
tcqttgaatc 
tgacctt cqc 
ttgacggcc.g 
gaggcggtgg 
gtgatggtgg 
gaaattag 
Wall 
Phe 
Glu 
Glin 
6 O 
Gly 
Ser 
Thir 
45 
Ser 
Gly 
Ile 
3O 
Gly 
Met 
Val Gly 
15 
Phe Ser 
Glu Thir 
Asn. Ser 
Gly Arg 
8O 
Gly Tyr 
95 
Tyr Gly 
Gly Gly 
Asn 
ggt caccggc 
gaaggittatic 
Ctcagagcag 
taaCat Cact 
titt.cgaagt 
ttct cqctac 
Lieu Ala 
15 
Tyr Gly 
Arg Ser 
Lys Asp 
432 
6 O 
12 O 
18O 
24 O 
3OO 
360 
408 
46 
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Gly Gly Gly Gly 
115 
Ser Tyr Gly Gly Gly 
12 O 
Gly Gly Arg 
125 
Gly Gly 
13 O 
Ser 
14 O 
Tyr Ser Gly Gly Gly Ser 
135 
Gly Gly Tyr Arg 
Gly Glu 
145 
Gly Ser Tyr Gly Gly 
150 
Gly Arg Arg Gly 
155 
Gly Gly 
Gly Gly Glu Gly Gly 
1.65 
Gly Gly Gly Ser 
17O 
Gly Gly Gly 
What is claimed is: 
1. A method of increasing the innate immunity exhibited by 
a soybean plant comprising: 
introducing a transgene into a plurality of soybean cells to 
produce transgenic soybean cells, wherein the transgene 
comprises a nucleic acid sequence having at least 99% 
sequence identity to the nucleotide sequence of SEQID 
NO: 33 encoding soybean glycine rich RNA binding 
protein as set forth in SEQ ID NO. 34, wherein the 
nucleic acid sequence is operably linked to a promoter 
functional in Soybean cells; 
regenerating transgenic soybean plants from the transgenic 
Soybean cells; 
identifying at least one of said transgenic soybean plants 
expressing said transgene encoding said soybean gly 
cine rich RNA binding protein; 
exposing at least one of said transgenic Soybean plants 
expressing said transgene encoding said soybean gly 
cine rich RNA binding protein to a biotic stress; and 
identifying at least one of said transgenic soybean plants 
that exhibits increased innate immunity in response to 
the biotic stress relative to a control plant. 
2. The method of claim 1, wherein said transgene com 
prises the nucleic acid sequence of SEQID NO:33. 
3. The method of claim 1, wherein said biotic stress is 
selected from the group consisting of a pathogen-induced 
stress and a wound-induced stress. 
Arg Glu Gly 
Gly Gly 
Gly Tyr 
Gly Gly 
15 
25 
30 
35 
Gly 
Gly 
Gly 
160 
Trp 
17s 
4. The method of claim 1, wherein the promoter is a con 
stitutive promoter. 
5. A method of increasing the innate immunity exhibited by 
a Soybean plant comprising: 
introducing a transgene into a plurality of soybean cells to 
produce transgenic soybean cells, wherein the transgene 
comprises a nucleic acid sequence that encodes a 
polypeptide having the amino acid sequence of SEQID 
NO:34, wherein the nucleic acid sequence is operably 
linked to a promoter functional in Soybean cells; 
regenerating transgenic Soybean plants from the transgenic 
Soybean cells; 
identifying at least one of said transgenic soybean plants 
expressing said transgene encoding said polypeptide; 
exposing at least one of said transgenic Soybean plants 
expressing said transgene to a biotic stress; and 
identifying, at least one of said transgenic soybean plants 
that exhibits increased innate immunity in response to 
the biotic stress relative to a control plant. 
6. The method of claim 5, wherein said biotic stress is 
selected from the group consisting of a pathogen-induced 
stress and a wound-induced stress. 
7. The method of claim 5, wherein the promoter is a con 
stitutive promoter. 
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